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1. Introduction  
 
1.1. Myeloid lineage commitment: granulopoiesis versus monopoiesis 
 
All living organisms are continuously exposed to substances that are capable of causing 
them harm. To protect themself higher organisms have developed a general defence 
mechanism, the immune system, which is made up of a complex network of cells, tissues, 
and organs that work together. The key players mediating the organism’s protection are 
specialized immune cells that arise from multipotent hematopoietic steam cells (HSCs). 
Through the life, these highly proliferative and self-renewal HSCs are responsible for the 
development, maintenance, and regeneration of a multifaceted repertoire of mature blood 
cells that differentiate during a highly regulated process known as haematopoiesis. As the 
first step of such a differentiation process multipotent HSCs commit either to the myeloid 
or lymphoid lineage by differentiating to common myeloid progenitor (CMP) or common 
lymphoid progenitor (CLP) [1;2]. The CLP in turn gives rise to T, B and natural killer 
(NK) cells, whereas the CMP further differentiates into the granulocyte monocyte 
progenitor (GMP) or the megakaryocyte erythrocyte progenitor (MEP). Finally the GMP 
dives birth to the myelopoietic cell types we are interested in - granulocytes and monocytes 
[3;4] (Fig. 1). 
 
The lineage choice of the bi-potent GMP precursor to either granulocytic or monocytic 
direction was shown to be driven by the differential expression of complex network of 
lineage specific transcription factors [5]. Thus, C/EBPα was found to be preferentially 
expressed in and required for granulocytic commitment, whereas, for example, cJun was 
shown to promote monocyte differentiation [6;7]. An overview on the most critical 
transcription factors driving the granulocytic versus monocytic differentiation is illustrated 
in Figure 2. 
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Figure 1. Haematopoiesis - schematic representation of the lineage 
differentiation. The hematopoietic stem cell (HSC) gives rise to the common myeloid 
progenitor (CMP) or common lymphoid progenitor (CLP). CLP further differentiates to T, 
B or natural killer (NK) cells, whereas the CMP gives rise to the granulocyte monocyte 
progenitor (GMP) or the megakaryocyte erythrocyte progenitor (MEP). Next, the MEP 
commits either to the megacaryocyte or the erythrocyte lineage, whereas the GMP further 
differentiates into granulocytes or monocytes. Furthermore basophils and eosinophils arise 
from the CMP. Figure adapted from Myatt S. et al [8]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Transcriptional network of monopoiesis versus granulopoiesis. 
Transcription factors, critical for the monocytic versus granulocytic lineage 
differentiation, are listed in the corresponding boxes. 
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The process of myeloid differentiation was shown to be regulated by signals of the local 
microenvironment including the hematopoietic cytokines, which are found in the bone 
marrow where they act on the different progenitors such as the CMPs and drive their 
differentiation into mature myeloid cells. Cytokine binding to the cognate cell-surface 
receptors in a stage- and lineage-specific manner triggers the activation of the intracellular 
signal transduction pathways that facilitate the differentiation process. The diverse 
signalling pathways may thereby promote myelopoiesis by stimulating expansion of a 
progenitor pool, supporting cellular survival, or by directly driving the phenotypic changes 
associated with differentiation. Ultimately, the specific signalling mediators that trigger the 
differentiation process converge on myeloid transcription factors that are critical for 
terminal commitment [4;9;10].  
 
1.2. Activation and signalling of the MAP kinase pathway 
 
Cellular behaviour in response to extracellular stimuli is mediated through intracellular 
signalling pathways such as the mitogen-activated protein kinase (MAPK) pathways. The 
MAPK pathways transduce a variety of external signals, leading to a wide range of cellular 
responses, including growth, differentiation, inflammation and apoptosis [11;12]. Like 
other cascades the MAPK signalling cascade serves as an amplifying mechanism to 
enhance the upstream signal intensity on the way to the downstream targets found in the 
nucleus. The signal transduction thereby begins from the MAP kinase kinase kinases 
(MAPKKKs), which are activated by an external stimulus [13]. The MAPKKKs next 
activate the MAP kinase kinases (MAPKK), which in turn activates the downstream MAP 
kinases (MAPK) [14] (Fig. 3). MAPK are among the most ancient and evolutionarily 
conserved signal transduction pathways transferring stimuli from the cell surface to the 
nucleus [15]. Three major groups of MAPKs have been identified in mammalian cells: the 
extracellular signal-regulated protein kinases (ERK), the cJun N-terminal or stress-
activated protein kinases (JNK/SAPK), and the p38 MAPK. The JNK family is thereby 
composed of JNK1, JNK2, and JNK3, while the ERK kinase group includes two members 
(ERK1 and ERK2). The p38MAPK family consists of 4 different isoforms (p38α, p38β, 
p38γ, and p38δ) that share significant structural homology [16]. Activation of the various 
MAPKs is mediated via dual phosphorylation on threonine (Thr) and tyrosine (Tyr) 
residues present in specific motifs (ThrXaaTyr). Such phosphorylation is regulated by 
upstream dual-specificity kinases, the MAPKKs, which are capable of phosphorylating 
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MAP kinases on both serine/threonine, as well as on tyrosine residues. The MAPKKs 
thereby exhibit relative specificity for the substrate MAPK proteins that they 
phosphorylate. MKK1 and MKK2 phosphorylate ERK kinases; MKK3, MKK4, and 
MKK6 phosphorylate p38 kinases, while MKK4 and MKK7 regulate dual phosphorylation 
of JNK kinases [17;18] (Fig. 3). Interestingly, MAPKKs also exhibit relative specificity for 
the different isoforms that they target within each group of MAPKs. For instance, among 
the different p38MAPK subtypes, MKK6 functions as a common activator of all four 
isoforms (p38α, p38β, p38γ, and p38δ), while MKK3 activates p38α, p38γ, and p38δ, but 
not p38β [19].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The MAPK signalling cascades. 
External stimuli trigger the activation of MAPKKK, which in turn activates a MAPKK. Next, MAPK is 
activated and transduces the signal into the nucleus, modulating transcriptional networks. Figure adapted 
from Thalhamer T. et al [20].  
 
The proliferation and differentiation of hematopoietic cells is known to be regulated by 
various cytokines and growth factors that activate the MAPK signalling pathways to 
generate their effects. Among them, pro-inflammatory cytokines were shown to modulate 
myeloid differentiation via the MAPK signalling cascade [21;22].  
 
 
Nucleus
Inflammatory cytokines/mediators              
Stress                                                  
Growth factors
MEKK1-4 MLK3
MKK4MKK3/6
p38
Ras/Rap
Raf
MKK1/2
ERK1/2
MEKK1/4 TAK1
MKK4/7
JNK1/2/3
ASK1
Transcription Factors
MAPKKK
MAPKK
MAPK
TFs
Introduction 
 7
1.3. Transcriptional mechanism of granulocytic versus monocytic differentiation – 
the role of C/EBPα and cJun 
 
The process of myeloid differentiation is tightly regulated by differential expression of 
lineage specific transcription factors. Generally, lineage commitment has been considered 
to be an irreversible event: once a progenitor loses its multipotency, it never regains the 
lost developmental potentials. However, resent studies provide increasing evidence for 
lineage plasticity [10].  
 
The CCAAT enhancer binding protein α (C/EBPα) is one of the key transcription factors 
that mediate lineage specification and differentiation of multipotent myeloid progenitors 
into mature granulocytes. It is a member of the basic-region leucine zipper (bZIP) DNA 
binding transcriptions factors. This family is characterized by the presence of a basic 
region that mediates DNA binding and a leucine zipper that allows dimer formation. In 
addition to forming homodimers, C/EBPα also dimerizes with other members of the 
C/EBP family and interacts with other proteins [23]. A recent study demonstrated a direct 
interaction of C/EBPα with the monocytic transcription factor cJun during granulocyte 
differentiation. The C/EBPα/cJun dimerization blocks the positive feedback regulation of 
the cJun expression, therefore allowing granulocytic lineage commitment [24]. In addition, 
several other investigations highlighted the indispensability of C/EBPα for granulocytic 
differentiation. For example, C/EBPα null mice were shown to lack mature granulocytes, 
while all other blood cell types were present [25]. In contrast, increased levels of C/EBPα, 
expressed from an inducible promoter construct, directed the differentiation of bi-potential 
myeloid cells along the granulocytic pathway. Furthermore, it was demonstrated that the 
ectopic expression of C/EBPα can prevent TPA-induced monocytic differentiation of bi-
potential myeloid progenitor cells [26].   
 
AP-1 (activating proteins 1) are sequence-specific bZIP transcription factors composed of 
homodimers or heterodimers of the Jun family (cJun, JunD, and JunB) or heterodimers of 
the Jun family member with any of the Fos family members (c-Fos, FosB, Fra1, and Fra2) 
or other transcription factors [7;27]. Members of the AP-1 family are regulated both at the 
transcriptional and the posttranscriptional level by MAPKs [28]. The activity of the Jun 
family member we are interested in, cJun, is regulated by posttranslational modifications 
such as phosphorylation [29]. The phosphorylation of Ser-63 and Ser-73, located within 
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the N-terminal transactivation domain, was shown to potentiate the ability of cJun to 
activate transcription [30]. Furthermore, it could be demonstrated that such activated cJun 
is able to autoregulate its expression through a cJun/AP-1 enhancer element in its own 
promoter [31]. Numerous studies highlighted cJun as a critical regulator of monocytic 
differentiation. As an example exogenous cJun expression was shown to induce monocyte 
differentiation of bi-potential myeloid cells. Furthermore, commitment along the 
monocytic lineage is known to be accompanied by cJun upregulation [32;33].  
 
1.4. The role of MKK6-p38MAPK signalling in chronic inflammatory diseases such 
as rheumatoid arthritis 
  
Rheumatoid arthritis (RA) is the prototype of a chronic inflammatory disease in humans. 
Chronic inflammatory processes are based on a sustained and tightly regulated 
communication network among different cell types. This network comprises extracellular 
mediators such as cytokines, chemokines, and matrix degrading proteases, participating in 
inflammatory processes as well as in the bone and cartilage destruction, which is 
characteristic for RA [34;35].  
The development and severity of RA was found to be dependent on pro-inflammatory 
cytokines such as IL-1 and TNFα that can activate a broad array of intracellular signal 
transduction mechanisms [36]. Among the cytokine- and stress-activated pathways, MAP 
kinases are especially important in such disorders as they were shown to increase the 
production of several mediators of inflammation and cartilage damage [37]. The 
p38MAPK is of particular interest in RA as it is know to play a major role in the 
production of pro-inflammatory cytokines including IL-1 and TNFα by activating 
transcription factors binding to the corresponding promoter regions [38]. Furthermore, 
p38MAPK participates in other inflammation-related events, such as neutrophil activation, 
apoptosis, and nitric oxide synthase induction [39-41]. Interestingly, p38MAPK was 
shown to be expressed and activated in the inflamed synovial tissue, suggesting a critical 
role in RA [42].  
A differential tissue expression and activation of the described p38MAPK isoforms (p38α, 
p38β, p38γ, and p38δ) was found in the inflamed tissues of patients with RA. The isoforms 
p38α and p38γ were the most abundantly expressed and predominantly activated. The 
expression of p38MAPKs was localized to the synovial lining layer and to the blood 
vessels. Furthermore, monocytes/macrophages, synovial fibroblasts and granulocytes 
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found in the inflamed tissue showed p38MAPK expression, whereas lymphocytes were 
rarely positive for any p38 isoform [42]. Interestingly, the distinct p38 isoforms were 
found to have opposite effects on the regulation of cJun transcription as well as activation 
in terms of phosphorylation. Thus, p38β was shown to induce cJun phosphorylation 
whereas, in contrast, the γ and δ isoforms seem to inhibit cJun trans-activation by upstream 
MAPKK [27].  
Although the impact of p38MAPK in the development of chronic inflammatory diseases 
was extensively examined little is known about upstream kinases, that activate these 
pathways in joint tissues [43]. Among the MAPKKs, MKK3 and MKK6 are thought to be 
especially important regulators of p38MAPK and represent potential therapeutic targets to 
modulate pro-inflammatory cytokine production [44]. Both MKK3 and MKK6 are 
activated upon phosphorylation of serine and threonine residues by upstream MAPKK 
kinases. Upon activation, MKK3 selectively phosphorylates p38α, γ, and δ whereas MKK6 
activates all four p38 isoforms (α, β, γ, and δ) [45;46], which were shown to have opposing 
effects on cJun activation [27]. Due to the fact, that the MAP kinase kinase MKK6 is able 
to activate all known p38 isoforms, the response downstream of p38MAPK is thought to 
be determined by the specific expression patterns of the p38MAPK family members.  
 
1.5. In vitro differentiation of distinct myeloid cell subsets 
 
A variety of myeloid cell subsets can be differentiated in vitro from hematopoietic stem 
cells. An established system used in our lab allows the generation of distinct myeloid 
lineages out of CD34+ cord blood stem cells. As the first step of the differentiation process 
the multipotent progenitor cells are expanded in the presence of a defined cytokine cocktail 
mimicking the natural environment found in the bone marrow [5]. After expansion, 
differentiation into desired myeloid cell subsets is achieved by the corresponding critical 
cytokines depicted in Figure 4. As an example, the differentiation of granulocytes and 
monocytes is driven by G-SCF and M-CSF/IL-6, respectively. Validation of differentiation 
can be achieved by morphological examination monitored by microscopy, as well as by the 
determination of the expression of the subset specific surface markers (Fig. 4) with FACS 
analysis. The described differentiation procedures illustrate a facile system for the in vitro 
generation of various myeloid cell subsets [47].  
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Figure 4. In vitro differentiation system for the 
generation of distinct myeloid cell subsets. Cytokines critical 
for the commitment of the corresponding myeloid lineage (monocytes 
(MO); granulocytes (G); monocyte-derived dendritic cells (moDC); 
Langerhans cells (LC)) as well as the subset specific surface markers are 
depicted in black. 
 
1.6. Lineage characteristic cell surface markers 
 
To characterize the lineage specificity of the in vitro differentiated myelopoietic cells the 
expression levels of subset specific markers have to be determined by FACS analysis. In the 
current study we are interested in two particular lineages, granulocytes as well as 
monocytes. As depicted in Figure 3, granulocytes show expression of CD15, CD11b, 
CD66b, lactoferrin (LF), and myeloperoxidase (MPO), whereas high expression levels of 
CD14 and CD11b are characteristic for monocytes. An overview highlights the prominent, 
cell type characteristic functions of the G- versus Mo-specific markers (Table 1). 
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Table 1.  Expression markers characteristic for the granulocytic and monocytic 
lineages 
CD15 carbohydrate adhesion molecule; expressed on glycolipids and 
glycopoteins on the neutrophils surface and to some extend on 
monocytes; mediates chemotaxis, cell-cell interactions and 
phagocytosis [48-50]. 
CD66b GPI-anchored glycoprotein; exclusively expressed on human 
granulocytes; an granulocytic activation marker; localizes in lipid 
rafts and interacts with other cell surface molecules, such as CD11b; 
mediates the adhesion to E-selectin [51;52]. 
Lactoferrin    
(LF) 
Glycoprotein; member of the transferrin family; found in the 
secondary granules of neutrophils and broadly distributed within 
body fluids; important component of the innate immune system with 
an antimicrobial activity; broad spectrum of functions: regulation of 
iron homeostasis, host defence against a broad range of microbial 
infections, anti-inflammatory activity, regulation of cellular growth 
and differentiation [53-56]. 
Myeloperoxidase 
(MPO) 
Heme protein; major component of neutrophil azurophilic granules; 
produces hypohalous acids, a potent oxidant implicated in the 
microbicidal activity of neutrophils and tissue destruction [57;58]. 
CD11b Integrin alpha M chain; important for the adherence of neutrophils 
and monocytes to stimulated endothelium, and phagocytosis of 
complement coated particles; forms transmembrane signalling 
complexes with GPI-anchored glycoproteins [59;60]. 
CD14 Myeloid-specific leucine rich repeat (LRR) protein; abundant on 
mature monocytes and macrophages; pattern recognition receptor, 
acts as a co-receptor for LPS [61;62].  
CD86 Type I membrane protein; expressed by antigen-presenting cells; 
ligand for CD28 and CTLA-4 at the surface of T cells [63-65]. 
 
 
 
Introduction 
 12
1.7. Inducible gene expression - the Tet-on retroviral gene transductions system  
 
The in vitro differentiation approach enables the generation of a variety of myeloid cell 
subsets from CD34+ cord blood stem cells. To analyse the impact of distinct signalling 
cascades on commitment as well as on function of myelopoietic cells the Tet-on gene 
transduction system can be used. This method allows the retroviral tranduction of CD34+ 
progenitors with a gene of interest, followed by the induction of gene expression at any 
time point of the differentiation process. In the described system CD34+ cord blood stem 
cells are sequentially transduced with two retroviral vectors. The first vector encodes a 
tetracycline activator (TA) and the second vector bears the gene of interest under the 
control of a tetracyclin response element (TRE) (Fig. 5). To induce gene of interest 
expression doxycycline has to be added. For the examination of the impact of a factor of 
interest on cell commitment the transduced gene can be turned on at the desired time point 
of the differentiation process, whereas for functional analysis within terminally 
differentiated cells gene induction can be performed at the end of the differentiation period. 
In addition, this established procedure for primary cells can be furthermore adapted for any 
cell line. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Tet-inducible gene transduction system. 
Sequential transduction with two retroviral vectors: the Tet-activator 
and the Tet-response vector. Tet-activator vector encodes the 
tetracycline activator (TA) and the expression marker mouse CD8α. 
The Tet-response vector contains a multiple cloning site (MCS) for 
the introduction of a gene of interest; a tetracycline response element 
(TRE) controlling the expression of the introduced gene; the 
expression marker NGFR or GFP.  
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2. Aim of the study  
 
In the current study we aim to assess the role of the MAP kinase signalling pathway within 
myelopoiesis. We focus on one prominent family member, MKK6, as well as its 
downstream effector p38MAPK and their impact on the plasticity of the myelopoietic 
sublineage differentiation. Preliminary results from our laboratory suggest the MKK6 
signalling cascade to be able to redirect granulocytic cells to the monocytic lineage. 
Central to this study is the investigation of the molecular mechanisms that underlie the 
conversion process. Of particular interest are MKK6-p38MAPK induced alterations of 
transcriptional regulators. Furthermore, we aim to elucidate external stimuli capable to 
trigger the conversion process and test various combinations of pro-inflammatory 
cytokines, known to induce MAPK signalling, for their ability to reprogram granulocytic 
cells to monocytes. Based on the obtained findings we provide a model whereby 
committed granulopoietic cells undergo monocyte differentiation under inflammatory 
conditions. 
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3. Reagents, buffers, and solutions  
 
 
Table 2. Self-made buffers and solutions 
Buffer/Solution Components 
X-vivo + Glutamax              
+ Pen/Strep 
X-vivo15 medium (BioWhittaker)  +  GlutaMAX                 
(2.5 mM; Gibco/Invitrogen) + penicillin/streptomycin  
(125 U/mL each; Sigma) 
DMEM + 10% FCS             
+ Glutamine + Pen/Strep 
DMEM (Sigma) + 10 % Foetal Bovine Serum (Gibco) +       
L-Glutamin (2 mM; Sigma) + penicillin/streptomycin            
(125 U/mL each; Sigma) 
RPMI + 10% FCS               
+ Glutamine + Pen/Strep 
RPMI (Sigma) 10 % Foetal Bovine Serum (Gibco) +             
L-Glutamin (2 mM; Sigma) + penicillin/streptomycin         
(125 U/mL each; Sigma)  
dH2O Aqua bidest. “Fresenius” (Fresenius Kabi) 
2xHBS 8 g NaCl; 6.5 g HEPES; 105 mg Na2HPO4 in 500 ml H2O 
(pH 7.0) 
RetroNectin  90µl RetroNectin (1mg/ml; Takara Bio) in 3 ml 1xPBS 
Beriglobin  Beriglobin (CSL Behring) diluted 1:8 in PBS/BSA/Azid 
4xSampleBuffer 0.5M Tris/HCl (pH 6.8); 40% glycerol (Roth); 4% SDS 
(Roth); 5 µl/ml Bromphenolblue (Roth);                                 
5% Mercartoethanol (Sigma) 
2xSamleBuffer/Tris-Base 0.5 ml 4xSample Buffer; 0.5 ml Tris-base (pH 11) 
Separating gel (10%) 2667 µl 30% Acrylamid/Bis (29:1) (BioRad); 2000 µl 
Tris/HCl pH 8.8; 3203 µl H2O; 40 µl 20% SDS (Roth);         
80 µl 10% APS (Roth); 10 µl TEMED (BioRad) 
Stacking gel (4%) 396 µl 30% Acrylamid/Bis (29:1) (BioRad); 378 µl 
Tris/HCl pH 6.8; 2196 µl H2O; 15 µl 20% SDS (Roth);        
20 µl 10% APS (Roth); 5 µl TEMED (BioRad) 
10x SDS-PAGE runnig 
buffer 
30.2 g Tris (Roth); 144 g Glycin (Roth); 10 g SDS (Roth) 
in 1000 ml H2O 
10x Blotting buffer 30,3 g Tris (Roth); 144 g Glycin in 1 L H2O 
Stripping buffer 100 ml SDS (Roth); 62.5 ml 1M Tris HCl pH 7.5;                  
7.3 ml β-Mercaptoethanol (Sigma); 830.2 ml dH2O 
Reagents, buffers, and solutions 
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10x PBS 400 g NaCl (Roth); 10 g KCl (Roth); 72 g Na2HPO4 
(Roth); 10 g KH2PO4 (Roth); adjust to pH 7,4; in 5 L H2O 
1x PBST 1xPBS/ 0.05% Tween (Tween20; Roth) 
10x TBS 24.2 g Tris Base; 80 g NaCl in 1 L dH2O                                
(pH adjusted to 7.6) 
1x TBST 1xTBS/0.05% Tween (Tween20; Roth) 
1x PBS/BSA/Azid 1xPBS; 20% BSA (Roth); 0,4% Na3N (Roth) 
Hunt Buffer 20 µM Tris-HCl (pH 8); 100 µM NaCl (Roth); 1 mM 
EDTA (Roth); 0,5% NP-40 (Calbiochem Novabiochem 
Corporation) 
Dephosphorylation 
Buffer 
50 mM Tris-HCl (pH 8); 1 mM MgCl2; 0.5% TX-100 in 
dH2O 
50xTAE Buffer 242 g Tris/HCl; 57.1 ml acetic acid; 37.2 g 
Na2EDTA.2H2O in 1 L H2O 
5X KCM Buffer 0.5 M KCl ; 0.15 M CaCl2 ; 0.25 M MgCl2 in dH2O 
SOC-medium 2 g tryptone (Roth); 0.5 g yeast extract; 1 ml 1 M NaCl 
(Roth); 0.25 ml 1 M KCl (Roth); 1 ml 2 M Mg2+ (Roth);       
1 ml 2M glucose (Roth) in 100 ml H2O  
LBAmp medium LB medium (10 g tryptone (Roth); 5 g yeast extract (Roth);  
5 g NaCl (Roth); 100 µg/ml Ampicillin (Applichem) 
LBAmp plates 15 g agar (Roth) in 1L LBAmp medium 
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4. Material and Methods 
 
4.1. Cell lines 
 
PhoenixE cells were maintained in DMEM + 10% FCS + Glutamine + Pen/Strep on cell 
culture dishes (Nunclon™∆ Surface, Nunc). HL60-TA-NFGR and HL60-TA-d.a.MKK6 
cells were cultured in RPMI + 10% FCS + Glutamine + Pen/Strep in cell culture flasks 
(Nunclon™∆ Surface, Nunc). All cell lines and primary cells were maintained at 37°C in 
the 5% CO2 incubator. 
 
4.2. Granulocyte and monocyte differentiation 
 
Granulocytes (G) and monocytes (Mo) were in vitro differentiated from CD34+ stem cells 
isolated from cord blood of healthy donors [47]. After isolation the CD34+ cells were 
expanded for 3 days in X-vivo + Glutamax + Pen/Strep medium supplemented with SCF     
(50 ng/ml), Flt3L (50 ng/ml), and TPO (50 ng/ml). For G differentiation 2x104/ml cells 
were transferred into the granulocyte-mix (X-vivo + Glutamax + Pen/Strep medium 
supplemented with G-CSF (100 ng/ml) and SCF (20 ng/ml)) and cultured for additional 11 
days. For Mo commitment, cells were cultured for 10 days in the monocyte-mix (X-vivo + 
Glutamax + Pen/Strep medium supplemented with M-CSF (100 ng/ml), IL-6 (20 ng/ml), 
SCF (20 ng/ml), and Flt3L (50 ng/ml)). All cytokines used were obtained from PeproTech. 
 
4.3. Stimulation with pro-inflammatory cytokines 
 
In vitro differentiated granulocytes, monocytes and HL60 cells were stimulated with 
different combination of pro-inflammatory cytokines (GM-CSF; GM-CSF/TNFα;        
GM-CSF/TNFα/IL-1β; TNFα/IL-1β) for 48 h (primary cells) or 72 h and 96 h (HL60 cell 
line). Following cytokines and final concentrations were used: GM-SCF (10 ng/ml), TNFα 
(25 ng/ml) and IL-1β (10 ng/ml). For control purpose HL60 cells were additionally 
stimulated with ATRA (1 µM) and VitD3 (25 ng/ml). GM-SCF, TNFα and IL-1β were 
obtained from PeproTech; ATRA and VitD3 were from Sigma. 
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4.4. Retroviral infection and gene transduction 
 
For retroviral infection of HL60-TA-NFGR and HL60-TA-d.a.MKK6 cells with the 
control vector (pMCSV(puro) or HR-I-GFP) or the vector of interest (pMCSV(puro)-
antisense cJun; HR-I-GFP-antisense cJun; HR-I-GFP-DN cJun), the PhoenixE (PhE) 
packaging cell line and a calcium-phosphate precipitation method were used. The infection 
procedure was performed according to the Nolan Lab protocol for retroviral transfection 
[www.stanford.edu/group/nolan]. For optimal transfection efficiency PhE cells were 
freshly plated onto a 6 cm dish 24 h prior to transfection to reach sub-confluent stage. 
Next, the transfection mix [10 µg DNA; 61 µl 2M CaCl2; 430 µl bdH2O; 500 ml 2xHBS] 
was prepared, vortexed for 10 sec and incubated for 15 min at room temperature (RT). 
During incubation time, 3 µl 50 mM Chloroquin (Sigma) were added to the cells for 10 
min at RT followed by a drop wise addition of the transfection mix. The PhE cells were 
incubated with the DNA precipitates for 6 h at 37°C. Next, the medium was removed and a 
fresh medium (DMEM + 10% FCS + Glutamine + Pen/Strep) was added. After 48 h of 
incubation the first infection cycle was performed. The supernatant of transfected PhE cells 
was collected and the plates were subsequently supplemented with a fresh medium. Next, 
the supernatant was filtered (0.45 µm filter, IWAKI) and 500 µl/well were transferred on a 
24-well-suspension plate (CellStar suspension culture plate, Greiner) for 3 h to 6 h at 37°C. 
Prior to the addition of the viral supernatant, the suspension plates were pre-coated with 
300 µl/well RetroNectin (Takara Bio) overnight at 4°C followed by RetroNectin removal 
and blockage with 1 ml/well DMEM + 10% FCS + Glutamine + Pen/Strep for 15 min at 
RT. Upon expiration of the incubation period, 300 µl of the virus containing supernatant 
were removed and 1x105 HL60-TA-NFGR or HL60-TA-d.a.MKK6 cells in 500 µl 
medium were added onto the virus pre-coated plate and incubated with the virus overnight. 
Then, the second infection cycle was performed. 500 µl medium was removed from the 
infected cells followed by the addition of 500 µl fresh viral supernatant collected from PhE 
cells and purified as described above. Six hours after infection, 500 µl medium was 
removed followed by an addition of 500 µl fresh RPMI + 10% FCS + Glutamine + 
Pen/Strep and an incubation at 37°C overnight. Next day, the cells were collected, washed 
three times with 1xPBS (Sigma) and resuspended at the desired cell density in RPMI + 
10% FCS + Glutamine + Pen/Strep. In case of the pMSCV(puro) vector the cells were 
selected in the presence of puromycin (2µg/ml; Sigma) for 10 days. 
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4.5. Modulation of the d.a.MKK6 expression levels/p38MAPK activation  
 
To induce the expression of d.a.MKK6 alone or in combination with the gene of interest 
(e.g. antisense cJun or dominant negative cJun), doxycycline (2 µg/ml; Sigma) was added 
for the time period of 48 h to HL60-TA-d.a.MKK6 cells. 
To modulate the expression levels of d.a.MKK6 and thereby p38MAPK activation various 
concentrations of doxycycline (0.1 µg/ml, 0.25 µg/ml, 0.75 µg/ml, 2 µg/ml, and 4 µg/ml) 
were used.  
To block the signal transduction downstream of MKK6 the p38MAPK inhibitor 
(SB203580, Calbiochem) and the JNK inhibitor (SP600125, Calbiochem) were used. The 
corresponding inhibitor was added at the final concentration of 10 µM to HL60-TA-
d.a.MKK6 cells simultaneously with the d.a.MKK6 induction by doxycycline. 
The applied Tet-on system allows to restrict the expression of d.a.MKK6 to a desired time 
period. Three experimental approaches were used to achieve transient induction of the 
MKK6-p38MAPK signalling cascade. (I) The “dox washing” method: after induction by 
doxycycline for indicated time periods (2 h, 4 h, 6 h, and 8 h) HL60-TA-d.a.MKK6 cells 
were washed twice with 1xPBS and resuspended in fresh medium. (II) Use of p38MAPK 
inhibitor: the p38MAPK inhibitor was added to HL60-TA-d.a.MKK6 cells after 6 h of 
d.a.MKK6 induction. (III) Combinatorial approach: 6 h after d.a.MKK6 induction HL60-
TA-d.a.MKK6 cells were washed to remove the doxycycline followed by the addition of 
p38MAPK inhibitor. 
 
4.6. Inhibition of the proteasome machinery 
 
To analyse the mechanism that underlies the MKK6-triggered C/EBPα downregulation the 
proteasome inhibitor (MG132, PeptaNova) at 10 µM was added to the HL60-TA-
d.a.MKK6 cells 6 h after the induction of d.a.MKK6. 
 
4.7. SDS-PAGE and Western blot analysis 
 
Cells were washed with 1xPBS, resuspended in the appropriate volume of 2xSampleBuffer 
(1x105 cells/10µl) and lysed by heating at 95°C for 5-10 min. Proteins were resolved by a 
10% SDS-PAGE and transferred to a PVDF membrane (Immobilon Transfer Membranes; 
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Millipore) at 100 V for 90 min using a Bio-Rad Criterion Blotter (Bio-Rad). After the 
transfer the membranes were blocked with 5% dry milk in 1xPBST or 10% BSA in 
1xTBST for 1 h at RT followed by the incubation with the primary antibody overnight at 
4°C. Next, membranes were washed three times for 5 min with 1xPBST or 1xTBST 
followed by the addition of the horseradish peroxidase (HRP)–conjugated secondary 
antibody for 1-2 h at RT. Table 3 summarizes the primary and secondary antibodies used.  
 
Table 3. List of primary and secondary antibodies 
Antibody Dilution Second step Company 
P-MKK3/6 
(Ser189/207) 
1:1000                         
in 5%BSA/TBST 
anti-rabbit-HRP Cell Signalling 
P-p38 MAPK 
(Thr180/Tyr182) 
1:1000                      
in 5%BSA/TBST 
anti-rabbit-HRP Cell Signalling 
P-SAPK/JNK 
(Thr183/Tyr185) 
1:1000                      
in 5%BSA/TBST 
anti-rabbit-HRP Cell Signalling 
p38 1:1000                      
in 5%BSA/TBST 
anti-rabbit-HRP Cell Signalling 
MKK6 1:500                        
in 2.5%Milk/PBST 
anti-rabbit-HRP BioLegend 
SAPK/JNK 1:1000                      
in 5%BSA/TBST 
anti-rabbit-HRP Cell Signalling 
P-cJun               
(Ser63) 
1:1000                      
in 5%BSA/TBST 
anti-rabbit-HRP Cell Signalling 
Jun 1:750                        
in 2.5%Milk/PBST 
anti-mouseHRP BD Pharmingen 
C/EBPα 1:250                        
in 2.5%Milk/PBST 
anti-goat-HRP Santa Cruz 
Biotechnology 
KLF4 1:1000                      
in 2.5%Milk/PBST 
anti-goat-HRP Santa Cruz 
Biotechnology 
actin 1.1000                      
in 2.5%Milk/PBST 
anti-rabbit-HRP Sigma-Aldrich 
Secondary antibody Dilution  Company 
goat anti-rabbit IgG 1:2500   Pierce 
Biotechnology 
goat anti-mouse IgG 1:5000   Pierce 
Biotechnology 
donkey anti-goat IgG 1:1000   Santa Cruz 
 
Secondary antibodies that were used for probing of membranes blocked with dry milk 
were diluted in 2.5% dry milk in 1xPBST. Dilution of secondary antibodies in 5% BSA in 
1xTBST was used for BSA-blocked membranes. Membranes that were probed with more 
that one primary antibody were each time stripped with stripping buffer for 15 min at 60°C 
and re-blocked prior to the application of the subsequent antibody. Detection was 
performed with the chemiluminescent substrate SuperSignal WestDura Extended Duration 
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Substrate or the SuperSignal WestPico Rabbit IgG Detection Kit (Pierce Biotechnology). 
Lumi-ImagerTM or the Fujifilm Las-4000 were used for data imaging. For densitometric 
analysis ImageJ was used. 
 
4.8. Protein Dephosphorylation by Alkaline Phosphatase 
 
To perform dephosphorylation, proteins had to be extracted using the                             
Hunt Buffer. The cell pellet (2-4x106 cells) was resuspended in 100 µl Hunt Buffer, 
supplemented with the protease inhibitor (Roche) and the phosphatase inhibitor (Roche) 
and frozen in liquid nitrogen. Next, the sample was thawed at RT followed by re-freezing 
in liquid nitrogen. Finally the pellet was thawed at 37°C, frozen again and centrifuged for 
30 min at 14000 rpm/4°C. Protein extracts were stored at -80°C. For protein 
dephosphorylation 50 µl protein extract were resuspended in 1 ml dephosphorylation 
buffer. 0.5 ml of the protein extract solution was kept untreated and used as a negative 
control while to the remaining extract (0.55 ml) 20 µl of calf intestinal alkaline 
phosphatase (CIAP; 1 U/µl; Fermentas) were added. To achieve dephosphorylation 
samples were incubated for 1 h at 37°C. For protein precipitation TCA (Roth) was added at 
the final concentration of 10%. The samples were incubated on ice for 30 min followed by 
centrifugation (10min/16000g/4°C). The pellet was washed once with 500 µl ice-cold 
acetone (Roth) and spun down (10min/16000g/4°C). Finally, the protein pellet was 
resuspended in 15 µl 2xSamle Buffer/Tris-Base and kept at -20°C for further use. 
 
4.9. FACS staining 
 
Cells were collected and washed twice with 1xPBS (centrifugation at 300 g/4 min/4°C), 
resuspended in the appropriate volume of 1xPBS to reach a concentration of 5x104-5x105 
cells per 50 µl. To block unspecific binding 1/10 volume Beriglobin was added and 
incubated for 10-15 min on ice. 50 µl cell suspension were transferred into micronic tubes 
(Thermo Scientific) followed by the addition of 10 µl primary antibody (directly 
conjugated to the flurochrome or biotin conjugated) for 30 min at 4°C. Subsequently, cells 
were washed twice with 1xPBS/BSA/Azid and the second step antibody (Streptavidin-
PerCP) was added and incubated for 30 min at 4°C. Next, the cells were either prepared for 
FACS by washing once with 1xPBS/BSA/Azid and once with 1xPBS or, in case of an 
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subsequent intracellular staining, first fixed by the addition of 100 µl Fixation Medium  
(An Der Grub) for 5 min at RT. After fixation, cells were washed and permeabilized by the 
addition of 100 µl Permeabilization Medium (An Der Grub) followed by an incubation 
with 10 µl of antibody directed against intercellular proteins for 30 min at 4°C.  
The following murine monoclonal antibodies (mABs) were used: FITC-conjugated mAbs 
specific for CD15, CD86 (BD Pharmingen); phycoerythrin (PE)-conjugated mAbs specific 
for CD11b, (BD Pharmingen), LF (intracellular) (An Der Grub);  Biotinylated mAbs 
specific for CD11b, NGFR (BD Pharmingen);  allophycocyanin (APC)-conjugated mAbs 
specific for CD14 (Caltag Laboratories); second step streptavidin (SA)-PerCP                
(BD Pharmingen). All antibodies were pre-diluted 1:5 with 1xPBS/BSA/Azid in exception 
of APC-CD14 (1:30), LF (1:2), and SA-PerCP (1:100). The flow cytometric analysis was 
performed using a LSRII (BD Biosciences). Data were analyzed with CellQuest Pro 
software (BD Biosciences). 
 
4.10. RNA isolation and cDNA generation 
 
For RNA isolation the RNeasy Mini Kit (QIAGEN) was used. Cells were lysed in 350 µl 
RLT buffer (QUIGEN) supplemented with β-Mercaptoethanol (10µl per 1000µl RTL) by 
vortexing for 30 sec. Upon disruption samples could be stored at -80°C. For RNA 
isolation, 350 µl 70% EtOH were added and the sample was transferred to the RNeasy 
column and centrifuged for 15 sec at 8000 g. The column was washed with 350 µl RW1 
buffer (15 sec/8000 g) followed by the addition of 80 µl of a DNase solution (10 µl DNase 
I stock solution; 70 µl RDD buffer) and incubation for 15 min at RT. Next, the column was 
washed with 350 µl RW1 buffer (15 sec/8000 g) followed by an additional washing with 
500 µl RPE buffer (15 sec/8000 g) and PRE buffer (2 min/8000 g). To remove the residual 
fluid the column was further centrifuged at full speed for 1 min. For RNA elution, RNase-
free water (20 µl) was used (1 min/8000 g). To increase the RNA yield the described 
elution procedure was repeated twice. 
16.25 µl of total RNA were used for cDNA generation. First, 1 µl 25 mM oligo T20 
primers (Fermentas) were added; for primer annealing the following PCR program was 
used: 5 min/70°C; 5 min/4°C. Next, 7.75 µl reverse transcription mix [5 µl RevertAid 
[TM] H Minus M-MuLV RT Buffer 5x (Fermentas); 1.25 µl 10 mM dNTP Mix 
(Fermentas); 0.5µl RiboLock[TM] RNase inhibitor (Fermentas); 1 µl ReveseAid[TM] H 
Minus M-MuLV RT (200 U/µl; Fermentas)] were added. The reverse transcription 
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reaction was performed at 42°C for 60 min followed by 15 min at 70°C and cooling to 
4°C. The cDNA stock was stored at -20°C. 
 
4.11. Real-time PCR 
 
For real-time PCR analysis the SYBR Green detection system was used. 10 µl Power 
SYBR® Green PCR Master Mix (Applied Biosystem) were mixed with 2 µl cDNA (1:5 
dilution with dH2O), 0.5 µl 10 µM forward primer, 0.5 µl 10µM reverse primer, and 7 µl 
dH2O. Table 4 summarizes the used primers. 
 
Table 4. Primers used for real-time PCR 
cJun F- 5’ GAGGGGGTTACAAACTGCAA 3’    
R- 5’ TCTCACAAACCTCCCTCCTG 3’ 
C/EBPα F- 5’ TTGTCACTGGTCAGCTCCAG 3’   
R- 5 ’TGGACAAGAACAGCAACCAG 3’ 
KLF4 F- 5’ GCCGCTCCATTACCAAGA 3’  
R- 5’ GTGCCTTGAGATGGGAACTC 3’ 
GAPDH F- 5’ GAAATCCCATCACCATCTTCCAGG 3’ 
R- 5’ CGCGGCCATCACGCCACAGTTTCC 3’ 
 
All primers were designed using the Primer3 design tool and were obtained from MWG. 
The used primers spanned exon–intron boundaries, so they do not detect signals from 
possible co-amplified genomic DNA. Expression profiling was performed in a 96-well 
plate on the StepOne™ Real-Time PCR System (Applied Biosystems) using the following 
program: 10 min/95°C; [15 sek/95° C; 1 min/60°C] x 40 cycles and 15 sec/95°C;                
1 min/60°C at the melting curve step. Based on melting curve analysis no primer dimers 
were generated during the applied 40 real-time PCR amplification cycles. For relative 
quantification, data were analyzed using the “Normalized Relative Quantification” method 
(LightCycler; Roche). Expression levels of target genes in cells were normalized to 
GAPDH and shown relative to unstimulated cells (time point 0). 
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4.12. Cloning of a dominant negative cJun into HR-I-GFP vector  
 
A dominant negative form of cJun (DN cJun), where the most important phosphorylation 
sites at positions S63, S73, T91, and T93 are changed to A was obtained from Chen G. et 
al [66]. As DN cJun was provided in the HM6 vector it had to be re-cloned into a retroviral 
vector, which then could be used for retroviral infections. For this purpose, the Tet-
inducible HR-I-GFP vector was chosen. Due to the absence of compatible restriction sites 
enclosing the insert in the donor vector (HM6) and the recipient vector (HR-I-GFP) the 
following cloning strategy was used: HM6-DN cJun was digested with HindIII [6 µl vector 
(1 µg/µl); 1 µl HindIII (10 U/µl); 6 µl Tango buffer 10x, and 1 µl dH2O were mixed and 
incubated for 2 h at 37°C followed by enzyme inactivation for 15 min at 65°C]. For DNA 
cleanup form enzymatic reaction the linearized vector was separated by agarose gel 
electrophoresis; the fragment was purified using the QIAquick Gel Extraction Kit 
(QIAGEN). Next, the generated 5’ extension was blunted with the use of the 5’-3’ 
polymerase activity of the Klenow polymerase [17 µl gel purified, HindIII linearized 
HM6-DN cJun; 3 µl Klenow buffer 10x (Fermentas); 2 µl 1mM dNTPs (Fermentas); 3 µl 
Klenow Fragment (2 U/µl; Fermentas) and 5 µl dH2O were incubated 30 min at 37°C 
followed by inactivation – 10 min/75°C]. As before, the purification from enzymes was 
performed by the usage of the QIAquick Gel Extraction Kit. Then an EcoRI digestion was 
performed [15 µl purified blunted HM6-DN cJun; 6 µl Tango buffer 10x; 3 µl EcoRI              
(10 U/µl; Fermentas); 6 µl dH2O – digestion at 37°C for 2 h, inactivation at 65°C for             
15 min] that gave rise to a DN cJun with the EcoRI end at the 3’site and an blunt end on 
the 5’ site. Simultaneously with the generation of the DN cJun fragment, HR-I-GFP vector 
was digested with EcoRI in combination with an blunt end generating restriction enzyme - 
HpaI [1.4 µl HR-I-GFP vector (2.19 µg/µl); 1.5 µl EcoRI (10 U/µl); 3 µl HpaI (10 U/µl); 
4µl Tango buffer 10x; 10 µl dH2O – digestion at 37°C for 1 h, inactivation 65°C/15 min]. 
Finally, the ligation of the DN cJun into the HR-I-GFP vector was performed. To estimate 
the amounts of vector and insert, which will be used for ligation an analytic 1% agarosegel 
was run. Based on the intensities of the corresponding bands, 0.8 µl vector and 9 µl insert 
were used for ligation in the buffer containing 2 µl T4 DNA Ligase buffer 10x 
(Fermentas); 2 µl PEG 6000 (Fermentas), 1 µl T4 DNA Ligase (5 U/µl; Fermentas) and 
5.2 µl dH2O. The reaction was performed overnight at 16°C.  
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4.13. Cloning of cJun antisense into HR-I-GFP 
 
A cJun antisense construct was kindly provided by Grondin et al [67].  Since the antisense 
cJun was obtained in the pMSCV (puro) vector that does not contain a detection marker, 
the insert had to be re-cloned into the green fluorescent protein (GFP) expressing, Tet- 
inducible HR-I-GFP vector. The antisense cJun was cut out from the pMSCV vector by 
EcoRI digestion [6 µl pMSCV-cJun antisense (1 µg/µl); 3 µl EcoRI (10 U/µl); 6 µl Tango 
buffer 10x; 15 µl dH2O – digestion at 37°C for 2 h, inactivation 65°C/15 min]. 
Simultaneously, the digestion of the HR-I-GFP with EcoRI was performed as described 
above. Subsequently both linearized vector as well as the fragment were purified from 1% 
agarose gel and ligated [1 µl vector; 1 µl insert; 2 µl tango buffer 10x; 2 µl PEG 6000; 1 µl 
T4 DNA Ligase (5 U/µl); 13 µl dH2O – overnight ligation at 16°C].  
 
4.14. Agarose gel electrophoresis 
 
Upon digestion with restriction enzymes the obtained fragment was loaded on a 1% 
agarose gel [1 g agarose (Seakem LE Agarose; Biozyme) was dissolved in 100 ml 1x TAE 
Buffer and 10 µl Ethidium Bromide (Roth) were added]. The gel was run using the Bio-
Rad Sub-Cell GT system (Bio-Rad) in 1xTAE. The bands were visualized using the Lumi-
ImagerTM. 
 
4.15. Purification/DNA extraction from agarose gel 
 
To extract the desire fragments out of the agarose gel the QIAquick Gel Extraction Kit 
(QIAGEN) was used. According to the protocol 3x volume of QG buffer was added to 1x 
volume of the excised gel fragment and dissolved at 50°C for 10 min. Next, 1x volume of 
isopropanol (Roth) was added. To bind DNA, sample was applied on the QIAquick 
column and centrifuged 1 min at 13000 rpm. To remove trace amounts of agarose the 
column was washed with 0.5 ml of QG buffer (1 min/13000 rpm). Additional washing was 
performed using 0.75 ml PE Buffer (prior to centrifugation the column membrane was 
incubated with the applied PE buffer for 5 min at RT). To remove residual fluid the 
column was centrifuged for 1 min at 13000 rpm followed by elution. Therefore 30 µl dH2O 
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were added to the centre of the membrane, incubated for 1 min, and then centrifuged         
(1 min/13000 rpm).  
 
4.16. Transformation of KCM competent cells 
 
KCM competent cells were stored at -80°C. As the first step, KCM cells were thrown on 
ice for 10 min. In the meantime 20 µl 5x KCM buffer were mixed with 1 ul-10 µl DNA 
(ligation product) and filled up to 100 µl with dH2O. The DNA mix (100 µl) was added to 
the competent cells, mixed gently, and incubated on ice for 20 min followed by incubation 
at RT for 10 min. Then, 900 µl SOC-medium were added and the mix was incubated for 
40-60 min at 37°C/shaking. Finally, the cell suspension was transferred on LB+Amp plates 
and grown overnight in the 37°C incubator.  
 
4.17. Plasmid preparation 
 
For the purification of low amounts of plasmid DNA the GeneJETTM Plasmid Miniprep Kit 
(Fermentas) was used. A single colony was inoculated in 2 ml LBAmp medium and 
incubated overnight at 37°C/shaking. Next, the bacterial culture was harvested by 
centrifugation at 8000 rpm for 2 min at RT. The pellet was resuspended in 250 µl 
Resuspension Solution; 250 µl Lysis Solution were added followed by mixing by 
inverting. In addition, 350 µl Neutralization Solution were added, mixed and centrifuged 
for 5 min at 13000 rpm. The supernatant was transferred to the GeneJETTM spin column 
followed by centrifugation (1 min/13000 rpm). The column was washed twice by addition 
of 500 µl Wash Solution and centrifugation (1 min/13000 rpm). To remove residual 
solution the column was centrifuged (1 min/13000 rpm) followed by plasmid elution. 
Therefore 50 µl dH2O were added onto the column membrane, incubated for 2 min at RT 
and centrifuged for 2 min at 13000 rpm.  
To confirm the presence of the desire insert in the purified plasmid the insert was cut out 
by the usage of restriction enzymes, which were used for cloning. Furthermore, the right 
orientation of the cloned fragment was confirmed by additional digestion.  
To purify high amounts of plasmid DNA the QIAfilter Plasmid Maxi Kit (QIAGEN) was 
used. As the first step a single colony was inoculated in 2 ml LBAmp medium and a started 
culture was grown at 37°C/shaking for 8 hours. Next, the started culture was transferred in 
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100 ml LBAmp medium and an overnight culture was grown. The bacterial cells were 
harvested by centrifugation (5000 g/15 min/4°C). The plasmid DNA purification was 
performed according to the protocol. The bacterial pellet was resuspended in 4 ml P1 
Buffer, 4 ml P2 Buffer were added and mixed by inverting followed by an incubation 
period of 5 min at RT. Next, P3 Buffer (4 ml) was added, mixed and the lysate was applied 
into the QIAfilter Cartridge. During the subsequent incubation period (10 min at RT) the 
precipitate floated and formed a layer at the top of the solution thereby enabling successful 
filtration. In the meantime a QIAGEN-tip 500 column was equilibrated by applying 10 ml 
QBT Buffer. As next, the cell lysate was filtred trough the QIAfilter Cartridge into the 
equilibrated QUIAGEN-tip. The lysate then entered the column by gravity flow. The 
column was washed twice with 30 ml QC Buffer. Finally the plasmid DNA was eluted in 
15 ml QF buffer. To precipitate the DNA 10.5 ml isopropanol were added followed by 
centrifugation (1 h/5000 g at 4°C). The DNA pellet was washed with 5 ml 70% EtOH and 
centrifuged (1 h/5000 g at 4°C). The pellet was air dried and dissolved in 200 µl dH20. To 
determine the yield, DNA concentration was determined by spectrophotometry at 260 nm. 
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5. Results 
 
5.1. Stimulation with pro-inflammatory cytokines redirects granulocytic cells to 
monocytes 
 
Preliminary results of our lab showed that in vitro differentiated granulocytic cells (G) can 
be redirected to monocytes (Mo) by the overexpression of dominant active MKK6 
(d.a.MKK6). Interestingly, stimulation with pro-inflammatory cytokines also shifts the 
cells into the monocytic direction (Köffel et al, unpublished data). In the following 
experiment different combinations of pro-inflammatory cytokines were tested for their 
ability to reprogram granulocytic cells to monocytes. CD34+ cord blood stem cells were 
differentiated to granulocytes for 11 days in presence of G-CSF and SCF followed by 48 
hour stimulation with different cytokine cocktails. The cells were thereby either incubated 
with GM-SCF alone, in combination with TNFα, or with a TNFα/IL1β mixture. In 
addition, stimulation was performed with GM-CSF/TNFα/IL-1β, a cytokine cocktail 
mimicking the pro-inflammatory milieu found in the inflamed joins of rheumatoid arthritis 
(RA) patients [68-71]. For evaluation of phenotypic changes CD15+/LF+ granulocytes were 
analyzed by FACS for the expression of the monocytic marker CD14. Furthermore, 
western blot analysis was performed to examine the activation status of the MAPKK 
MKK6. 
As shown in Figure 6A, upon stimulation with pro-inflammatory cytokines the LF+ 
granulocytes lost their LF expression and simultaneously showed an upregulation of the 
monocytic marker CD14. Stimulation with the GM-SCF/TNFα and the TNFα/IL1β 
combination showed a potent monocyte induction capacity (data not shown). However, the 
most prominent shift into the monocytic direction could be achieved in case of the         
GM-SCF/TNFα/IL-1β cytokine cocktail (Fig. 6A). Furthermore, stimulation with the    
GM-SCF/TNFα/IL-1β was shown to trigger MKK6 activation as revealed by western blot 
analysis (Fig 6B).  
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Figure 6. Pro-inflammatory cytokines trigger G to Mo lineage shift via MKK6 
signalling cascade.  
(A) Stimulation with pro-inflammatory cytokines redirects G to Mo lineage differentiation. In vitro 
differentiated granulocytes (day 11) were stimulated with the GM-CSF/TNFα/IL-1β cytokine cocktail for    
48 h. Expression of granulocytic and monocytic markers was determined via FACS analysis. Cells showing 
the CD15+ phenotype were further examined for CD14 versus LF expression. (B) Pro-inflammatory 
cytokines trigger G to Mo switch via MKK6 activation. In vitro differentiated granulocytic cells (ctrl) were 
stimulated with GM-CSF/TNFα/IL-1β (GM-CSF/TNFα/IL-1β) or left untreated (w/o) for 48h. MKK6 
activation was determined by the P-MKK6 levels by western blot analysis. Re-probing with anti-actin 
antibodies served as loading control.  
 
 
5.2. MKK6-dependent granulocyte to monocyte conversion is accompanied by the 
upregulation of cJun and downregulation of C/EBPα 
 
Overexpression of d.a.MKK6 as well as stimulation with pro-inflammatory cytokines 
instructs granulocytic cells to acquire a monocytic phenotype. The phenotypic switch was 
found to be accompanied by changes in the expression levels of the critical transcriptional 
regulators of the monocytic and the granulocytic lineage, cJun and C/EBPα, respectively 
(Köffel et al, unpublished data). To further analyse the transcriptional changes that drive 
the G to Mo shift, in vitro differentiated granulocytes were stimulated with different 
combinations of pro-inflammatory cytokines for 48 hours and analyzed for the expression 
levels of the critical monocytic transcription factor cJun and the granulocyte promoting 
factor C/EBPα.  
As already demonstrated by FACS analysis, stimulation with GM-SCF/TNFα/IL-1β 
induced the most prominent shift into the monocytic direction. In line with the FACS data 
(Fig. 6A) this cytokine cocktail showed the strongest effect on the protein level. A potent 
induction of the monocytic transcription factor cJun as well as a marked downregulation of 
the granulocytic factor C/EBPα could be observed (Fig. 7).  
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Figure 7. Stimulation with pro-inflammatory cytokines 
triggers the upregulation of cJun and downregulation of 
C/EBPα. CD34+ progenitors were in vitro differentiated into granulocytic 
cells for 11 days followed by the stimulation with pro-inflammatory 
cytokines (GM-CSF; GM-CSF/TNFα; GM-CSF/TNFα/IL-1β; TNFα/IL-1β) 
for 48 h. Western blot analysis of cJun and C/EBPα levels. Re-probing with 
anti-actin antibodies served as loading control.  
 
 
5.3. Promyelocytic HL60 cells undergo Mo differentiation in response to d.a.MKK6 
 
To further analyze the molecular mechanisms of the MKK6-dependent granulocyte to 
monocyte conversion, promyelocytic HL60 cells were used. For this purpose a HL60 based 
cell line was chosen, which expresses a Tet-inducible d.a.MKK6-NGFR cassette upon 
induction by doxycycline (HL60-TA-d.a.MKK6). Cell surface NGFR expression was 
thereby used as a marker for successful d.a.MKK6 induction, as described previously [72]. 
Examination of the cell morphology revealed the acquirement of an adherent, 
inflammatory monocyte-like phenotype upon expression of d.a.MKK6 (Fig. 8A). In line 
with the morphological changes, an upregulation of the monocytic markers CD14 and 
CD11b as well as of the maturation marker CD86 could be observed upon expression of 
d.a.MKK6 in HL60 cells (Fig. 8B). Taken together, the morphological examination as well 
the analysis of surface marker expression demonstrated an MKK6-driven differentiation of 
promyelocytic HL60 into the monocytic lineage. 
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Figure 8. MKK6-triggered differentiation of HL60 cells. 
(A) Promyelocytic HL60 cells acquire a monocytic phenotype upon d.a.MKK6 
expression. (ctrl) unstimulated HL60-TA-d.a.MKK6 cells. (d.a.MKK6) HL60-TA-
MKK6 cells expressing d.a.MKK6 for 48 h. (B) Overexpression of d.a.MKK6 
drives HL60 cells into the monocytic direction. HL-60-TA-d.a.MKK6 cells were 
incubated with doxycycline for 48 h (+ dox) to trigger the d.a.MKK6 expression. 
Gated NGFR+ cells were examined for the surface expression of CD14, CD11b, and 
CD86 by FACS. Data are shown as mean values ± S.D. of three independent 
experiments. 
 
 
5.4. MKK6-dependent Mo conversion of HL60 cells is accompanied by a rapid 
induction of cJun and downregulation of C/EBPα  
 
To examine whether the MKK6-driven transcriptional changes observed in primary cells 
(Fig. 7) similarly occur in the HL60-TA-d.a.MKK6 system, the expression levels of the 
transcription factors of interest, cJun and C/EBPα, were analysed in a time kinetic 
experiment. Therefore the expression of d.a.MKK6 was induced by doxycycline for 2 h,     
4 h, 6 h, 8 h, 16 h, 24 h, and 48 h followed by western blot analysis.    
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Figure 9. Expression of d.a.MKK6 in HL60 cells 
triggers a rapid cJun upregulation paralleled by 
C/EBPα downregulation. Expression of d.a.MKK6 was 
induced in HL60 cells for indicated time periods. cJun and 
C/EBPα protein levels were determined by western blot. Actin 
served as loading control. 
 
 
Western blot analysis of HL60 cells revealed a rapid, time dependent cJun upregulation 
which is paralleled by C/EBPα downregulation upon d.a.MKK6 induction (Fig. 9). In line 
with the data observed for primary, in vitro differentiated granulocytic cells (Fig. 7, the 
shift to the monocytic direction was shown to be accompanied by the upregulation of cJun 
and downregulation of C/EBPα in the HL60-TA-d.a.MKK6 system. In conclusion, these 
data highlight the HL60 system as a valid model for further analysis of the molecular 
mechanisms of the MKK6-dependent G to Mo conversion. 
 
5.5. The reciprocal expression pattern of cJun and C/EBPα on the protein level is 
also reflected on a transcriptional level 
 
As the examination of cJun and C/EBPα expression on the protein levels revealed a 
reciprocal expression pattern (Fig. 9) we aimed to investigate whether the expression of 
these transcription factors was also regulated on the transcriptional level. To address this 
question, real-time RCR analysis was performed to examine cJun as well as C/EBPα 
mRNA levels at   2 h, 4 h, 6 h, 8 h, 16 h, 24 h, and 48 h post d.a.MKK6 induction.  
Real-time PCR results revealed an upregulation of cJun mRNA, starting at 2 h and 
reaching a plateau at 6 h after d.a.MKK6 induction. In contrast, C/EBPα mRNA levels 
showed a strong, up to ten fold, downregulation starting at 2 h and reaching the minimal 
levels at 16 h post d.a.MKK6 triggering (Fig. 10). In conclusion, these data demonstrate 
two key players of G versus Mo lineage differentiation, C/EBPα and cJun, to be tightly 
regulated in response to MKK6 signalling on both the transcriptional as well as the protein 
level. 
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Figure 10. Transcriptional regulation of cJun and C/EBPα levels 
accompany the MKK6-dependent monocyte differentiation of 
HL60 cells. Real-time PCR analysis of cJun and C/EBPα mRNA levels in HL60 
cells was performed at the indicated time points after d.a.MKK6 induction. 
Expression levels of target genes were normalized to GAPDH and shown relative to 
unstimulated cells (time point 0h). One representative result of two independent 
experiments is shown.  
 
 
5.6. MKK6-dependent C/EBPα downregulation via proteasome dependent 
degradation 
 
The MKK6-dependent granulocyte to monocyte shift is, as described above, associated 
with the downregulation of C/EBPα. Given that C/EBPα levels within cells are regulated 
via ubiquitinylation and subsequent proteasomal degradation [73] we made use of a 
proteasome inhibitor (MG132) [74] to investigate the mechanism that underlies the 
C/EBPα downregulation observed in our system. The expression of d.a.MKK6 was 
induced by doxycycline followed by the addition of the proteasome inhibitor at 6 hours 
post MKK6 induction. In parallel, for control purpose d.a.MKK6 expressing cells were 
cultured in the absence of inhibitor. Protein samples were collected from control HL60 
cells (ctrl), as well as from MG132 treated HL60 cells (MG132) at 0 h, 6 h, 7 h, 8 h, 9 h, 
and 10 h.  Figure 11A schematically illustrates the experimental setup.   
In comparison to the control cells, where starting from 7 h after d.a.MKK6 induction a 
marked C/EBPα downregulation occurred, the protein levels remained unchanged in the 
presence of the proteasome inhibitor (Fig. 11B). As prolonged treatment with MG132 
induces cell apoptosis, stabilization of C/EBPα levels could only monitored by short term 
0
2
4
6
8
10
0h 2h 4h 6h 8h 16h 24h 48h
re
la
tiv
e
ex
pr
es
si
on
 le
ve
ls
cJUN
C/EBPα
MKK6
Results 
 33
studies. In conclusion, the results demonstrate the MKK6-dependent C/EBPα 
downregulation to be based on proteasome dependent degradation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Inhibition of the proteasomal machinery by MG132. 
(A) Examination of the proteasome-dependent C/EBPα degradation - schematical 
representation of the experimental setup. Expression of d.a.MKK6 was induced in 
HL60-TA-d.a.MKK6 cells by the addition of doxycycline (0h). 6h post d.a.MKK6 
induction the proteasome inhibitor MG132 was added followed by an incubation 
period of 4 h. As a control in parallel d.a.MKK6 expressing HL60 cells were cultured 
in the absence of inhibitor. Protein samples were collected from control (ctrl) and 
MG132 treated cells (MG132) at indicated time points for western blot analysis.                     
(B) Stabilization of C/EBPα levels in the presence of the proteasome inhibitor. At 
the time point of 6 h post d.a.MKK6 HL60 cells were treated with the proteasome 
inhibitor MG132 for the period of 4 h. As a control d.a.MKK6 expressing HL60 cells 
cultured in absence of the inhibitor we used. C/EBPα protein levels were examined by 
western blot analysis at 0 h, 6 h, 7 h, 8 h, 9 h, and 10 h. Re-probing with anti-actin 
antibodies was used as loading control. 
 
 
5.7. MKK6-dependent cJun upregulation is accompanied by cJun phosphorylation 
 
The monocytic transcription factor cJun was shown to be upregulated during MKK6-
dependent granulocyte to monocyte conversion (Fig. 9). The activity of cJun is known to 
be regulated by posttranslational modifications such as phosphorylation [29]. 
Phosphorylation of Ser-63 and Ser-73 located within the N-terminal transactivation domain 
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potentiates the ability of cJun to activate transcription [30]. To examine whether cJun is 
phosphorylated in response to MKK6 during G to Mo shift we made use of an antibody 
that detects cJun only when phosphorylated on Ser-63. Expression of d.a.MKK6 was 
triggered in HL60 cells for 2 h, 4 h, 6 h, 8 h, and 48 h followed by western blot analysis.  
 
 
 
 
 
Figure 12. Phosphorylation of the N-terminal 
transactivation domain of cJun upon MKK6 
induction. HL60 cells were examined for the P-cJun (anti-phospho 
Ser-63 cJun antibodies) levels 2 h, 4 h, 6 h, and 8 h post d.a.MKK6 
induction. Actin served as loading control. 
 
Phosphorylated forms of cJun could be detected at 6 h and 8 h. In contrast, at 48 h only a 
minor or non-phosphorylated form of this transcriptional factor was observed (Fig. 12). 
The results were obtained using an antibody directed against one of the main 
phosphorylation sites (Ser-63) located in the N-terminal transactivation domain. 
Phosphorylation of this domain at more than one residue give rise to multiple 
phosphorylation forms that appear as double or tripped bands, as seen in Figure 12. 
 
In vitro protein dephosphorylation analysis was used as an additional strategy to validate 
the phosphorylation status of cJun in response to MKK6 signalling. Protein samples were 
collected from uninduced cells (0 h) or from cells stimulated for d.a.MKK6 induction       
(8 h). This was followed by in vitro dephosphorylation by the alkaline phosphatase 
(CIAP). As described in details in material and methods a special lyses and incubation 
buffer had to be used to allow the CIAP to be active. For control purpose, at each of the 
examined time points (0 h and 8 h), cells had to be treated under three different conditions: 
(i) collection in the normal sample buffer used for all WB analysis described above (Fig. 
13; ctrl - SB); (ii) collection in the special lysis buffer without subsequent CIAP addition 
(Fig. 13; ctrl); (iii) collection in the special lysis buffer followed by incubation of the 
protein extracts with the alkaline phosphatase (Fig. 13; CIAP).  
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Figure 13.  In vitro cJun dephosphorylation by CIAP. 
Protein extracts were collected from uninduced HL60 cells or 8 hours upon 
d.a.MKK6 induction. In vitro protein dephosphorylation was performed by 
the usage of alkaline phosphatase (CIAP) as described in details in material 
and methods. cJun levels were determined via western blot using anti-cJun 
antibodies. Arrows indicate various phosphorylated forms. Re-probing with 
anti-actin antibodies served as loading control.  
 
As expected, no cJun could be detected in uninduced cells. In contrast, in line with 
previous results (Fig. 9) cJun was upregulated upon MKK6 induction. As can be seen in 
Figure 13 (ctrl - SB and ctrl) at the 8 hour time point the cJun signal was represented by a 
double band. The upper band likely corresponds to the phosphorylated form of this 
transcription factor whereas the lower one presumably represents a cJun form lacking post-
translational modifications. In the experiment in which the dephosphorylation was 
performed, the upper cJun band decreased, whereas the lower one increased 
simultaneously, thus demonstrating the conversion of phospho-cJun into non-
phosphorylated cJun. (Fig. 13; CIAP).  
In conclusion, the obtained data support that MKK6-induced cJun upregulation is 
accompanied by phosphorylation of the N-terminal transactivation domain. However, 
additional experiments are required to define the functional relevance of such post-
translational cJun modifications in the context of G to Mo lineage shift.  
 
5.8. Role of cJun in MKK6-dependent monocyte induction 
 
To further investigate the molecular mechanism of the MKK6-dependent granulocyte to 
monocyte switch we aimed to examine the role of cJun within the conversion process.  
As a strategy to interfere with cJun function, a dominant negative form of this transcription 
factor was used. Dominant negative cJun (DN cJun) was obtained from Chen G. et al [66] 
and represents a mutated form of cJun where the critical phosphorylation sites (S63, S73, 
T91, and T93) of the N-terminal transactivation domain [30;75] are changed to alanine. 
First, DN cJun had to be cloned in to a retroviral vector (Tet-inducible HR-I-GFP). Due to 
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the absence of compatible restriction sites the following cloning strategy was chosen, that 
is described in detail in material and methods. Briefly, the 5’ end of DN cJun was blunted 
by the 5’-3’ polymerase activity of Klenow polymerase; for the 3’ end a sticky end 
generating enzyme was used. In parallel the HR-I-GFP vector was cut with a blunt end 
generating enzyme in combination with a sticky end generating enzyme, used before for 
the generation of the 3’ of the DN cJun insert. Finally, DN cJun was cloned into the HR-I-
GFP. The obtained construct (HR-I-GFP-DN cJun) was retrovirally transduced into HL60 
bearing a Tet-inducible d.a.MKK6. This system allowed simultaneous induction of both 
d.a.MKK6 and DN cJun by the addition of doxycycline. FACS analysis was used to 
determine phenotypic changes. Furthermore, cJun and C/EBPα protein levels we examined 
by western blot.  
As shown in Figure 14A, strong induction of the monocytic marker CD14 was observed in 
control HL60 cells, expressing d.a.MKK6. In contrast, upon d.a.MKK6 plus DN cJun co-
induction HL60 cells showed a marked reduction of CD14 upregulation. CD11b, a marker 
of monocytes as well as granulocytes, showed only a tendency to downregulation in 
expression levels. The fact, that DN cJun was found to impede the MKK6-triggered G to 
Mo shift demonstrate the functional relevance of the post-translational phosphorylation of 
the N-terminal transactivation domain suggested to occur within the conversion process 
(Fig. 12). It furthermore highlights cJun as an indispensable key factor driving the lineage 
switch.  
In addition to the examination of the DN cJun effect on the HL60 phenotype, we 
performed western blot analysis for cJun and C/EBPα. As depicted in Figure 14B, 
d.a.MKK6 expressing HL60 cells which were co-transduced with DN cJun showed strong 
expression of this transcription factor (DN cJun; MKK6; 4h and 48h) in comparison to the 
cJun levels in controls cells, transduced with the empty HR-I-GFP vector (HR; MKK6; 4h 
and 48h). Expression of DN cJun did not stabilize C/EBPα levels, as downregulation of 
this granulocyte promoting transcription factor still occurred in the presence of the DN 
cJun construct. In conclusion, these results indicate a cJun-independent mechanism 
responsible for the MKK6-triggered C/EBPα degradation that takes place during the switch 
into a monocytic cell.  
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Figure 14. Expression of DN cJun in HL60-TA-d.a.MKK6 cells. 
(A) DN cJun interferes with MKK6-dependent monocyte differentiation.                
DN cJun (HR-I-GFP-TA-DN cJun) was introduced in HL60-TA-d.a.MKK6 cells via 
retroviral infection followed by doxycycline-mediated, simultaneous induction of 
d.a.MKK6 and DN cJun for 48 h (MKK6; DN cJun). As control, d.a.MKK6 expressing 
HL60 cells (MKK6; HR) or control HL60 cells lacking the d.a.MKK6 construct 
(CTRL; HR) were transduced with empty HR-I-GFP vector. Expression levels of the 
monocytic markers CD14 and CD11b were examined by FACS. The values are means 
± S.D. of three independent experiments. p<0.05 (*); p< 0.005 (**).                       
(B) Overexpression of DN cJun does not interfere with MKK6-dependent C/EBPα 
downregulation. HL60-TA-d.a.MKK6 cells were retrovirally transduced with empty 
control vector (HR) or dominant negative cJun (DN cJun). Protein levels of cJun and 
C/EBPα were analysed in uninduced cells (ctrl) or upon d.a.MKK6 induction (MKK6) 
at 4 h and 48 h time points. The same membrane was re-probed with anti-actin 
antibodies for loading control. 
 
 
In addition to the DN cJun approach described above, as the initial strategy, we tried to 
interfere with MKK6-triggered cJun upregulation via cJun knockdown by an antisense 
construct. An antisense cJun was obtained form Grondin et al [67] and introduced into 
HL60-TA-d.a.MKK6 cells using the retroviral gene transduction system. As the construct 
was provided in the MSCV(puro) vector that does not contain a detection marker but 
includes a puromycin resistance element, HL60 cells after infection had to be selected in 
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presence of puromycin. At the end of the selection period, the expression of d.a.MKK6 
was induced for 48 hours by addition of doxycycline. The cJun protein levels were 
examined by western blot. In parallel FACS analysis was used to determine the effect of 
cJun knockdown on the MKK6-dependent phenotypic shift.  
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Expression of antisense cJun in HL60-TA-d.a.MKK6 cells. 
(A) Antisense cJun inhibits MKK6-dependent cJun upregulation.  cJun protein levels were examined in 
control HL60 cells (ctrl) and HL60 cells retrovirally transduced with MSCV(puro)-antisense cJun 
(antisense-cJun) at 8 h after d.a.MKK6 induction. Actin served as loading control. (B) Antisense cJun 
interferes with MKK6-dependent monocyte induction. HL60-TA-d.aMKK6 cells were retrovirally 
transduced with the MSCV(puro)-actisense cJun (antisense-cJun) followed by selection in the presence of 
puromycin. Expression levels of CD14 and CD11b were determined by FACS after 48 h of d.a.MKK6 
induction.   
 
As demonstrated in Figure 15A MKK6-triggered cJun upregulation was reduced in the 
presence of the antisense construct, confirming the success of the knockdown approach. 
FACS results demonstrated a moderate diminishment of MKK6-dependent upregulation of 
monocytic markers CD14 and CD11b in the presence of the antisense cJun construct (Fig. 
15B).  
Since the approach described above showed only a moderate effect we next cloned 
antisense cJun into another vector, the Tet-inducible HR-I-GFP. In contrast to the 
MSCV(puro) vector used before the HR-I-GFP vector contains GFP as a detection marker 
and allows co-induction of the introduced antisense cJun simultaneously with d.a.MKK6. 
As before, the retroviral system was used for gene transduction followed by doxycycline-
mediated, simultaneous induction of both d.a.MKK6 and antisense cJun expression. 
However, in contrast to the expectation, significant abrogation of the MKK6-driven G to 
Mo shift could not be observed using the HR-I-GFP-antisense cJun construct. As one 
possible explanation we hypothesize that the strong cJun upregulation, triggered in 
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consequence of d.a.MKK6 overexpression, overtops the inhibitory capacity of the 
introduced antisense construct. Therefore, we decided to made use of another strategy to 
interfere with cJun and switched to the DN cJun approach, described above in detail.   
 
 
5.9. MKK6-dependent granulocyte to monocyte conversion is accompanied by the 
induction of KLF4, a critical regulator of monocyte differentiation  
 
KLF4, a member of the kruppel-like family of transcription factors was found to be highly 
expressed in monocytes. Furthermore, it was recently shown, that overexpression of KLF4 
in promyelocytic HL60 cells induces monocyte differentiation measured by CD14 and 
CD11b upregulation [76]. Therefore, we were interested whether this critical regulator 
could be involved in the observed phenomena of MKK6-triggered G to Mo conversion. To 
address this question, HL60 cells expressing d.a.MKK6 as well as control cells (HL60-TA-
NFGR) were examined for the KLF4 expression on the mRNA level by real-time PCR 
analysis as well as on protein level by western blot. 
Real-time PCR analysis revealed that KLF4 mRNA was upregulated up to 5-fold after                  
48 hours of d.a.MKK6 expression. In contrast, KLF4 expression levels in controls cells 
lacking d.a.MKK6 remained unchanged (Fig. 16A). In line with the real-time PCR results 
marked upregulation of KLF4 protein levels could be detected in HL60 cells expressing 
d.a.MKK6 (MKK6), whereas control cells (NGFR) showed stable KLF4 expression            
(Fig. 16B). As KLF4 induction could only be observed at the latest time point of 48 hours, 
it seems to lag behind the cJun and C/EBPα expressional changes that were shown to occur 
shortly upon MKK6 induction (Fig. 10). Based on these findings KLF4 upregulation is 
probably attributed to secondary effects of d.a.MKK6 signalling and seems not to be linked 
to the first wave of MKK6-dependent transcriptional changes.  
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Figure 16. MKK6-dependent KLF4 induction. 
(A) MKK6-triggered induction of KLF4 mRNA levels. HL-60 cells expressing 
d.a.MKK6 (MKK6) or control cells (NGFR) were examined for KLF4 mRNA levels 
by real-time PCR. Expression level of the target gene was normalized to GAPDH and 
shown relative to unstimulated cells (0h). A representative result of two independent 
experiments is shown. (B) MKK6-dependent KLF4 upregulation on the protein 
level. KLF4 protein levels were determined in HL-60 cells expressing d.a.MKK6 
(MKK6) as well as control cells (NGFR) at different time points (0 h, 24 h and 48 h). 
Actin served as a loading control.   
 
 
5.10. The transcriptional changes downstream of MKK6 are dependent on the 
p38MAPK signalling 
 
Overexpression of d.a.MKK6 in the promyelocytic HL60 cells was shown to induce 
upregulation of cJun accompanied by its phosphorylation, and the downregulation of 
C/EBPα.  (Fig. 9 and Fig. 12). Phosphorylation of the transactivation domain of cJun is 
known to be mediated by the cJun N-terminal kinase (JNK) [77]. In addition to the 
classical JNK pathway leading to the phosphorylation of this transcription factor resent 
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studies identified p38MAPK as a kinase directly phosphorylating cJun [78]. To examine 
which signalling pathway, downstream of MKK6, is responsible for the transcriptional 
changes within the observed monocyte lineage induction of HL60 cells we had a look at 
the activation status of both kinases. As it is known that p38MAPK as well as JNK are 
activated by phosphorylation [79] we analyzed the phosphorylation level of p38MAPK and 
JNK upon d.a.MKK6 induction in a time kinetic experiment.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. p38MAPK induced downstream of MKK6. 
Time kinetic analysis of protein levels upon d.a.MKK6 induction in HL60 
cells. p38MAPK and JNK activation was examined by the determination of 
phospho-p38 (P-p38) and phospho-JNK (P-JNK) levels, respectively. In 
addition cJun and C/EBPα protein levels were examined. Actin was used for 
loading control. 
 
Expression of d.a.MKK6 was found to induce strong p38MAPK activation as the 
phosphorylation level of p38MAPK was markedly increased starting from the 4 h time 
point (Fig. 17). In contrast, JNK phosphorylation levels remained unchanged (Fig. 17).  
 
Next, to further examine the signal transduction downstream of  MKK6 we made use of 
the specific p38MAPK inhibitor SB203580 [80] as well as the specific JNK inhibitor 
SP600125 [81]. The inhibitors were added to the HL60 cells simultaneously with the 
induction of d.a.MKK6; protein expression levels of cJun and C/EBPα were examined in a 
time kinetic experiment by western blot. In parallel, HL60 cells cultured in presence of the 
p38MAPK inhibitor were analyzed for the CD14, CD11b and CD86 induction by FACS at 
the 48 hour time point. 
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Figure 18. p38MAPK acts as the downstream effector of MKK6, diving G to Mo 
switch. 
(A) MKK6-dependent transcriptional changes are abrogated in presence of the p38MAPK inhibitor. 
The JNK inhibitor (SP600125) or the p38MAPK inhibitor (SB203580) was added to the HL60-TA-
d.a.MKK6 cells simultaneously with d.a.MKK6 induction by doxycycline. Expression levels of cJun and 
C/EBPα were determined in a time kinetic experiment by western blot analysis. The same membrane was 
re-probed with anti-actin antibodies for loading control. (B) The MKK6-dependent induction of a 
monocytic phenotype is abolished in the presence of the p38MAPK inhibitor. Expression of d.a.MKK6 
was induced in HL60-TA-d.a.MKK6 cells simultaneously with the addition of the p38MAPK inhibitor 
(SB203580). CD14/CD11b and CD86 expression levels were determined by FACS at the 48 h time point.  
 
As shown in Figure 18A, addition of the JNK inhibitor did not interfere with MKK6-
dependent transcriptional changes, in terms of cJun upregulation and C/EBPα 
downregulation. In contrast, the p38MAPK inhibitor showed a strong inhibitory effect. It 
abolished the MKK6-dependent cJun upregulation and, when normalized to the actin 
levels, showed to some extend stabilization of C/EBPα levels. In line with the results 
obtained on the protein level, FACS analysis revealed an abrogation of the MKK6-
dependent phenotypic changes in the presence of p38MAPK inhibitor. A marked 
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upregulation of CD14/CD11b (13% CD14+CD11b+; 19.3% CD11b+; 17.4% CD14+) and 
CD86 (80.1%) could be observed in control cells after d.a.MKK6 triggering. In contrast, 
HL60 cells treated with the p38MAPK inhibitor showed only a slight induction of these 
marker molecules (0.2% CD14+CD11b+; 7.3% CD11b+; 0.1% CD14+; 10.7% CD86+)   
(Fig. 18B).  
Taken together the obtained results demonstrate p38MAPK as the downstream effector of 
MKK6 driving G to Mo conversion.  
 
 
5.11. Physiological levels of p38MAPK activation are sufficient for the MKK6-
dependent monocyte induction 
 
To further investigate the molecular mechanism driving the granulocyte to monocyte 
lineage switch we aimed to examine which MKK6 expression and p38MAPK activation 
levels are sufficient to trigger a transcriptional program that is able to drive the cells into 
the monocytic direction. For this purpose HL60-TA-d.a.MKK6 cells were stimulated with 
various doxycycline concentrations ranging from 0.1 µg/ml up to 4 µg/ml. The 
acquirement of a monocytic phenotype was determined by FACS analysis. In parallel the 
MKK6-dependent transcriptional changes were analysed in a time kinetic experiment. 
As demonstrated by FACS, independently of the doxycycline concentration used for the 
initial d.a.MKK6 induction the HL60 cells showed a comparable upregulation of the 
monocytic markers CD14 and CD11b as well as the maturation marker CD86 (Fig. 19A).  
Similarly, on the protein level, a comparable MKK6 induction as well as p38MAPK 
activation was observed for the diverse doxycycline concentration (Fig. 19B). In line with 
similar p38MAPK phosphorylation pattern, a conformable cJun upregulation could be seen 
for all used doxycycline concentrations (Fig 19B). To quantify the effect of the 
doxycycline titration a densitometric analysis of the western blot results was performed. 
The ratio of phospho-p38 to p38 (P-p38/p38), representing the p38MAPK activation status 
was calculated for each individual time point. The obtained results were displayed by a 
graphical representation (Fig. 19C).  
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Figure 19. Modulation of MKK6 expression levels/p38MAPK activation. 
(A) Comparable induction of monocytic markers CD14 and CD11b as well as maturation 
marker CD86 for various doxycycline concentrations used for d.a.MKK6 induction. Titration of 
doxycycline (0.1 µg/ml, 0.25 µg/ml, 0.75 µg/ml, 2 µg/ml, and 4 µg/ml) used for the d.a.MKK6 
induction in HL60 cells. Expression levels of the cell surface markers CD14, CD11b and CD86 were 
determined by FACS at the 48 h time point. (B) Comparable levels of MKK6 induction, 
p38MAPK activation as well as cJun upregulation upon d.a.MKK6 induction with various 
doxycycline concentrations. Titration of the doxycycline concentration (0.1 µg/ml, 0.25 µg/ml,  
0.75 µg/ml, 2 µg/ml, and 4 µg/ml) used for the d.a.MKK6 induction in HL60 cells. p38MAPK 
activation, determined by phospho-p38 (P-p38) levels, and cJun induction was analyzed in a time 
kinetic experiment via western blot. Actin served as loading control. (C) Comparable p38MAPK 
phosphorylation levels after d.a.MKK6 induction with diverse doxycycline concentration. 
Graphical representation of the densitometric quantification of the western blot obtained from the 
doxycycline titration experiment. The P-p38/p38 ratio represents the activation status of p38MAPK. 
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Figure 19 (continued). Modulation of MKK6 expression levels/p38MAPK 
activation.  
(D) Non-saturated p38MAPK phosphorylation levels are sufficient to induce CD86 
upregulation. Graphical representation of the p38MAPK activation levels in correlation with 
induction of CD86. Densitometric analysis of the western blot signals at the corresponding 48 h time 
points was used to calculate the P-p38/p38 ratio. The corresponding surface expression levels of 
CD86 were determined via FACS analysis 48 h upon d.a.MKK6 induction. 
 
As depicted in Figure 19C, time kinetic analysis of the p38MAPK activation levels 
confirmed for all used doxycycline concentrations a similar, time dependent pattern of 
p38MAPK phosphorylation. Furthermore, the p38MAPK activation was shown to reach 
the plateau close to 100 % starting at the 8 h time point. An exception occurred in the case 
of the lowest doxycycline concentration (0.1µg/ml) where the p38MAPK phosphorylation 
did not exceed the level of 65 % during the time course analysis. 
An additional representation of the doxycycline titration analysis is depicted in Figure 
19D, where the correlation of P-p38/p38 to the induction of the monocytic maturation 
marker CD86 is illustrated. Although varying levels of p38MAPK phosphorylation were 
observed upon stimulation with various doxycycline concentrations a comparable CD86 
upregulation could be monitored (Fig. 19D). The most interesting example is the lowest 
doxycycline concentration (0.1 µg/ml) used for d.a.MKK6 induction: despite of the fact 
that a complete p38MAPK phosphorylation could not be achieved the HL60 cells showed 
a monocyte induction capacity (Fig. 19A), as well as the upregulation of the maturation 
marker CD86 comparable to the results obtained with 2 µg/ml doxycycline (Fig. 19D). 
In summary, the results demonstrate, despite of the tremendously high MKK6 levels 
emerging due to the d.a.MKK6 overexpression a time-dependent pattern of p38MAPK 
phosphorylation resulting in an exhaustive p38MAPK phosphorylation only in case of 
longer lasting MKK6 signalling. Furthermore, non-saturated phosphorylation levels were 
found to be sufficient to trigger maximal induction of a monocytic phenotype. In 
conclusion, these finding suggest moderate p38MAPK phosphorylation levels, mimicking 
the physiological situation, to be sufficient to drive the phenotypic switch. 
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5.12. Short term MKK6 induction is sufficient to redirect granulocytic cells to 
monocytes 
 
The next question we asked was whether it is necessary to overexpress d.a.MKK6 and 
thereby induce cJun upregulation and C/EBPα downregulation continuously during the 
granulocyte to monocyte conversion or if a transient MKK6 induction is sufficient to 
trigger a transcriptional program that then drives the cell into the monocytic direction. Two 
experimental approaches were used to address this question. First, to restrict the d.a.MKK6 
expression to the desired time period, we made use of the “dox washing“ method. HL60-
TA-d.a.MKK6 cells were transiently stimulated with doxycycline (2 h, 4 h, 6 h, and 8 h) 
followed by cell washing and subsequent culturing in fresh medium without doxycycline 
for up to 48 h (Fig. 20A). To examine the effects of such short term MKK6 induction on 
the MKK6-dependent transcriptional changes, protein samples were collected at the 
indicated time points as well as at the endpoint of 48 hours.  
In line with previous data (Fig. 9) continuous doxycycline stimulation triggers time-
dependent MKK6 overexpression, leading to upregulation of cJun and downregulation of 
C/EBPα (Fig. 20B, corresponding time points are depicted in red). In contrast, removal of 
doxycycline either at the 2 h, 4 h, 6 h, and 8 h time point resulted in a strong decline of the 
MKK6 levels detected at the corresponding 48 hour time points. As a consequence the 
MKK6-triggered cJun upregulation declined as well, reaching basal expression levels. In 
contrast, the downregulation of C/EBPα was not reversible in case of doxycycline removal 
(Fig. 20B). Taken together, the results highlight the “dox washing” approach as a suitable 
method for the restriction of the d.a.MKK6 signal transduction to a desired time period.  
Based on this finding the “dox wash” method was used to investigate whether a short term 
MKK6 induction would be sufficient to drive the promyelocytic HL60 cells into the 
monocytic direction. HL60-TA-d.a.MKK6 cells were induced by doxycycline followed by 
“dox washing “ after 4 h and 6 h of induction. The acquirement of the monocytic 
phenotype was monitored by FACS by gating on NGFR+ cells at the endpoint of the 
subsequent culture period of 48 hours.  
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Figure 20. Restriction of the MKK6-p38MAPK signalling cascade. 
(A) The “dox washing “ approach – schematical representation of the experimental setup. 
Control cells were continuously simulated with doxycycline over the culture period of 48 h. In 
the “dox washing” approaches the cells were washed 2 h, 4 h, 6 h, and 8 h after d.a.MKK6 
induction followed by subsequent culturing in a fresh medium without doxycycline till the 
endpoint of 48 h. Protein samples were collected at the indicated time points and at the endpoint 
of 48 h for western blot analysis. (B) Restriction of the d.a.MKK6 expression by the “dox 
washing” approach. HL60-TA-d.a.MKK6 cells were transiently stimulated with doxycycline 
for 2 h, 4 h, 6 h, and 8 h (time points indicated in red), washed and further cultured in a fresh 
medium for additional 48 h. Protein samples were collected at the corresponding time points and 
at the endpoint of 48 h. MKK6, cJun and C/EBPα levels were examined via western blot. Re-
probing with anti-actin antibodies served as loading control. (C) Short term MKK6 signalling 
is sufficient to redirect granulocytic cells to monocytes. The “dox washing” approach was 
used for HL60-TA-d.a.MKK6 cells to restrict the d.a.MKK6 induction to the desire time period 
(4h dox and 6h dox). For control sustained doxycycline stimulation was performed (ctrl (48h)). 
The upregulation of CD14, CD11b and CD86 was determined by FACS analysis of NGFR+ 
gated cells at the 48 h time point.  
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Figure 20 (continued). Restriction of the MKK6-p38MAPK signalling cascade. 
(D) Low levels of p38MAPK activation are sufficient to trigger a strong CD86 induction. 
Graphical representation of the p38MAPK activation in correlation with induction of CD86. HL60-
TA-d.a.MKK6 cells were transiently stimulated with doxycycline for 2 h, 4 h, 6 h, and 8 h, washed 
and further cultured in medium without doxycycline for additional 48 h. Sustained doxycycline 
stimulation was used as control (ctrl (48h)). The CD86 expression levels were determined via 
FACS at the endpoint of 48 h. TheP-p38/p38 ratio was calculated based on the densitometric 
analysis of the corresponding western blot signals.  
 
 
As demonstrated by FACS results, short term d.a.MKK6 expression (4 h or 6 h) triggered 
the upregulation of the monocytic markers CD14 and CD11b as well the maturation 
marker CD86 at the comparable levels to control cells where d.a.MKK6 induction 
sustained over a time period of 48 hours (Fig. 20C). Similar results were obtained when 
examining the total cell population (data not shown). In conclusion, the obtained data 
indicate that short term MKK6 signalling is sufficient to initiate a transcriptional program 
that then drives the cell into the monocytic direction. 
The correlation of the p38MAPK phosphorylation levels to the MKK6-triggered CD86 
induction was analyzed for the doxycycline titration experiments described above (Fig. 
19D). The results demonstrated a non-saturated p38MAPK phosphorylation to be 
sufficient to trigger a strong CD86 upregulation. The used doxycycline titration method 
represents an approach that allowed us to modulate the MKK6 signalling strength. In 
addition to that the “dox washing” method was used as a further strategy for the MKK6 
signal transduction restriction. To analyse the effects of the short term MKK6 induction on 
the activation of the downstream effector p38MAPK, the p38MAPK activation status was 
determined by the calculation of the P-p38/p38 ratio. The obtained results were correlated 
to the corresponding CD86 expression levels and depicted in a graphical representation 
(Fig. 20D). As shown in Figure 20D, short term pre-triggering of d.a.MKK6 for 2 h 
resulted in moderate CD86 induction and minor p38MAPK activation. In contrast, 4 h of 
d.a.MKK6 induction were already sufficient to induce a strong CD86 upregulation, 
although there was still a weak p38MAPK activation as depicted by the corresponding     
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P-p38/p38 value. Similar results were obtained for the 6 h time point. CD86 induction 
levels were comparable to the control cells, when d.a.MKK6 signalling sustained over 48 
hours (Fig. 20D; ctrl 48h), despite an incomplete p38MAPK activation of about 50%. An 
exhausting p38MAPK phosphorylation could only be achieved when the MKK6 was pre-
triggered for 8 h. The upregulation of the maturation marker CD86 in that case did not 
exceed the value of a short term induction for 4 h or 6 h. 
In summary, the obtained data demonstrate a correlation between the duration of the 
MKK6 signalling and the phosphorylation level of the downstream effector p38MAPK. 
Furthermore it once again highlights that low levels of p38MAPK activation, likely 
mimicking the physiological situation, are already sufficient to trigger the transcriptional 
program that redirects granulocytic cells to monocytes. Taken together, the results manifest 
the used HL60-TA-d.a.MKK6 system as a suitable in vitro model for the analysis of the 
MKK6-dependent granulocyte to monocyte switch as it recapitulates the key effects of 
signal transduction downstream of MKK6.  
 
In addition to the “dox washing” approach described above the MKK6 signalling cascade 
can be restricted for a desired time period by the inhibition of the downstream effector 
p38MAPK. For this purpose the p38MAPK inhibitor (SB203580) was used. It was added 
to the HL60 cells 6 hours after d.a.MKK6 induction. Furthermore, a combinatorial 
approach was performed where at the time point of interest, 6 hours upon d.a.MKK6 
induction, the cells were first washed to remove the doxycycline followed by the 
subsequent addition of the p38MAPK inhibitor. Phenotypic changes were analyzed by 
FACS at the endpoint of 48 hours. 
Control cells, which were continuously stimulated with doxycycline over a time period of 
48 hours (Fig. 21; + dox 48h (ctrl)), as anticipated, showed a strong upregulation of the 
monocytic markers CD14 and CD11b as well as the maturation marker CD86. A 
comparable conversion into a monocytic cell, as already shown before (Fig. 20C) could be 
observed in the approach where the “dox washing” was performed (Fig. 21; dox wash 6h). 
Restriction of signal transduction downstream of MKK6 by the p38MAPK inhibitor 
resulted in minor CD14 upregulation, in comparison to the control cells or the “dox 
washing” approach. However, the cells showed strong CD11b and CD86 induction, overall 
indicating a comparable shift into the monocytic direction (Fig. 21; SB 6h). Combinatorial 
approach revealed similar results regarding the markers expression. For control purposes 
an experiment was performed where the p38MAPK inhibitor was added simultaneously 
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with the d.a.MKK6 induction at the time point of 0 hours. In comparison to the approaches 
described above, those cells demonstrated only a minor upregulation of CD14, CD11b and 
CD86 (Fig 21; SB (ctrl)). One possible explanation for the slight induction of monocytic 
markers could be based on an incomplete inhibition of p38MAPK by the specific inhibitor 
within the period of 48 hours. 
 
 
 
 
 
 
 
Figure 21. Short term pre-triggering of the MKK6 signalling cascade is 
sufficient to drive monocyte differentiation. The MKK6-p38MAPK signal 
transduction was restricted to 6 h either by the “dox washing” method (dox wash 6h), the 
addition of the p38MAPK inhibitor SB203580 (SB 6h) or a combinatorial approach (wash/SB 
6h). Sustained doxycycline alone (dox 48h (ctrl)) or in combination SB203580 (SB (ctrl)) were 
used as controls. NGFR+ gated cells were examined for the CD14, CD11b and CD86 expression 
levels at the end of the culture period (48 h) by FACS.   
 
Taken together, the obtained results further indicate a short term induction of the MKK6-
p38MAPK signalling cascade to be sufficient to trigger a monocyte differentiating 
transcriptional program able to redirect the differentiation of granulocytic cell to the 
monocytic lineage.  
 
5.13. Stimulation with pro-inflammatory cytokines drives HL60 differentiation into 
the monocytic direction 
 
HL60-TA-d.a.MKK6 cells were used in numerous studies to examine the molecular 
mechanism of the MKK6-dependent granulocyte to monocyte conversion. They represent 
a suitable cell line model mimicking the MKK6-dependent phenotypic G to Mo switch 
observed in primary cells. Reprogramming of the in vitro differentiated granulocytes into 
monocytic cells can either be achieved by d.a.MKK6 overexpression or by the stimulation 
with pro-inflammatory cytokines. However, for HL60 cells, thus far, only the 
overexpression approach was used to induce monocyte differentiation. Therefore, we 
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aimed to investigate whether a stimulation with the GM-CSF/TNFα/IL-1β combination of 
pro-inflammatory cytokines, which was shown to have the most potent monocyte induction 
capacity in primary derived granulocytic cells, would similarly drive the HL60 cells into 
the monocytic direction. To address this question, HL60 cells were cultivated in the 
presence of GM-CSF, TNFα and IL-1β for 5 days, since a 48 hour stimulation used for 
primary cells showed only minor effects (data not shown). As a control HL60 cells were in 
addition stimulation with VitD3 or ATRA, which are known to induce monocyte and 
granulocyte differentiation, respectively [82]. Induction of CD14, CD11b and CD86 was 
determined by FACS. Additionally, the expression levels of the transcription factors of 
interest, cJun and C/EBPα, were monitored by western blot.  
As expected, stimulation with VitD3 triggered a potent shift into the monocytic direction 
as demonstrated by the strong induction of CD14+/CD11b+ double positive HL60 cells 
(81.7%) as well as by the upregulation of the maturation marker CD86 (30.2%). In 
contrast, HL60 cells cultured in presence of the granulopoiesis inducing agent ATRA [83] 
were directed into the granulocytic lineage as shown by the upregulation of CD11b (73%). 
In comparison to the monocyte induction, monitoring of granulocytic differentiation is not 
as well defined for HL60 cells, since they do not express the typical granulocyte markers, 
e.g. lactoferrin [82]. Therefore, only strong upregulation of CD11b, an integrin important 
for the adhesion of neutrophils and monocytes and for phagocytosis [84;85], can be used as 
a marker for granulocyte differentiation of HL60 cells. Results obtained for the stimulation 
with GM-CSF/TNFα/IL-1β suggest the induction of a monocytic phenotype, as 
demonstrated by CD11b (16.5%) and CD86 (7.1%) upregulation in combination with a 
slight shift into the CD14+ direction (Fig. 22A).  
In addition to the monitoring of phenotypic changes, assayed by surface marker 
expression, HL60 cells were examined for cJun and C/EBPα expression levels. Control 
cells expressing d.a.MKK6 showed the anticipated time-dependent upregulation of cJun 
paralleled by the downregulation of C/EBPα (Fig. 22B). In line with the data described 
above (Fig. 12), at the 8 h as well as 72 h time point the cJun signal was represented by a 
triple band, suggesting a MKK6-triggered phosphorylation of the N-terminal 
transactivation domain. Similar results were obtained for the stimulation with the 
monocyte inducing agent VitD3, where a comparable cJun upregulation likely paralleled 
by phosphorylation as well as the C/EBPα degradation were observed. In contrast, 
examination of HL60 cells cultured in presence of ATRA, which were found to be 
differentiated into granulocytes (Fig. 22A), revealed a C/EBPα downregulation, despite the 
Results 
 52
absence of a cJun induction (Fig.22B). The transcriptional changes observed for HL60 
cells stimulated with the GM-CSF/TNFα/IL-1β mixture of pro-inflammatory cytokines 
were in line with phenotypic shift estimated by FACS. A time-dependent cJun 
upregulation, paralleled by C/EBPα downregulation could be detected. Western blot results 
furthermore suggest a cJun phosphorylation, indicated by the appearance of a triple cJun 
band at the 72 h time point (Fig. 22B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Stimulation of HL60 cells with pro-inflammatory cytokines. 
(A) HL60 cells undergo monocyte differentiation upon stimulation with pro-inflammatory 
cytokines. HL60 cells were cultured in the presence of VitD3, ATRA or a combination of pro-
inflammatory cytokines (GM-CSF/TNFα/IL-1β) for 5 days. Cells were examined for the CD14/CD11b 
expression as well as CD86 induction by FACS. (B) Stimulation with GM-CSF/TNFα/IL-1β triggers 
the upregulation of cJun and the downregulation of C/EBPα. HL60 cells were stimulated with 
VitD3, ATRA, or a combination of pro-inflammatory cytokines (GM-CSF/TNFα/IL-1β) for 5 days. In 
parallel d.a.MKK6 was express in HL60-TA-d.a.MKK6 cells up to 5 days. cJun and C/EBPα levels 
were examined via western blot analysis. Actin served as loading control. 
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In conclusion, the obtained data demonstrate that similarly to CD34+ derived granulocytic 
cells the promyelocytic HL60 cells can be directed into the monocytic lineage by the 
stimulation with pro-inflammatory cytokines whereby in both cases the shift into the 
monocytic direction is accompanied by a reciprocal expression pattern of the key 
transcription factors cJun and C/EBPα. These findings further highlight the HL60-TA-
d.a.MKK6 system as a suitable model for the analysis of the MKK6-dependent granulocyte 
to monocyte switch. 
Discussion 
 54
6. Discussion 
 
Myeloid cells arise from multipotential hematopoietic stem cells (HSCs) that have the 
ability to differentiate into multiple cell types as well as to replenish the pluripotent 
population. The process of myelopoietic lineage decision is thereby tightly regulated by the 
differential expression of a complex network of subset specific transcription factors. 
However, there is no single transcription factor that is expressed exclusively by myeloid 
cells and that, alone, acts as a master regulator of myeloid fate choice. Rather, myeloid 
gene expression is thought to be controlled by the combinatorial effects of several key 
transcription factors. Traditionally, haematopoiesis has been viewed as linear and 
hierarchical, but there is increasing evidence of plasticity during myelopoietic 
commitment. Changes in the expression levels and timing of transcription factors were 
shown to be able to trigger lineage conversion of committed cells, indicating that the 
regulation of transcription factors might be primarily critical for maintaining hierarchical 
hematopoietic development [10;86].  
 
The herein applied in vitro differentiation system allows the generation of a variety of 
myelopoietic cells subsets from CD34+ cord blood stem cells. The commitment to a 
distinct lineage is driven by specific cytokines applied during the differentiation process. 
The validation of the in vitro generated myelopoietic cells of interest, granulocytes and 
monocytes, used in this study revealed the lineage characteristic morphology and the 
expression of the subset-specific surface markers depicted in Figure 4. In addition to the 
described in vitro differentiation strategy we made use of a retroviral Tet-on gene 
transduction system to identify a signalling cascade able to reprogram committed 
granulocytic cells. Usage of the Tet-on method allows a stable introduction of candidate 
signalling compounds into the CD34+ progenitors followed by the induction of the gene of 
interest either at desired time point within the differentiation process or at the end of the 
commitment period.  
 
Our data provides evidence that MKK6-p38MAPK signalling is able to reprogram 
committed granulocytic cells and redirect them to the monocytic lineage. In line with the 
results obtained from primary in vitro differentiated cells, signal transduction downstream 
of MKK6 similarly drives the differentiation of a promyelocytic HL60 cell line to the 
monocytic direction. Based on these findings, HL60-TA-d.a.MKK6 cells were chosen as a 
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suitable model for further investigations of the molecular mechanisms underlying the 
MKK6-dependent conversion process. The shift into a monocytic cell was found to be 
accompanied by the upregulation of the monocytic transcription factor cJun in parallel with 
a downregulation of the granulocyte promoting factor C/EBPα. As revealed by real-time 
PCR results and western blot analysis the reciprocal expression pattern appeared on the 
transcriptional as well as the protein levels. Time course analysis manifested the MKK6-
triggered changes in cJun and C/EBPα expression levels as primary transcriptional events, 
initiating G to Mo conversion. As it is known that the C/EBPα levels within cells are 
regulated via ubiquitinylation and subsequent proteasomal degradation [73] we asked 
whether the observed downregulation was based on a proteasomal degradation. To address 
this question we made use of an inhibitor of the proteasomal machinery. The obtained 
results showed a stabilization of C/EBPα protein levels in the presence of the proteasome 
inhibitor, indicating the MKK6-triggered C/EBPα downregulation to be based on a 
proteasome dependent degradation. Further investigations of the additional transcription 
factor that was found to be induced in a MKK6-dependent manner, cJun, suggested a 
phosphorylation of its N-terminal transactivation domain to occur within G to Mo 
conversion. To get insight into the functional relevance of such posttranslational cJun 
modification we transduced HL60-TA-d.a.MKK6 cells with a dominant negative form of 
this transcriptional factor (DN cJun). DN cJun was found to impede the MKK6-triggered G 
to Mo shift highlighting cJun as a key player driving G to Mo lineage conversion. The 
classical view on the signal transduction of mitogen-activated protein kinase pathways 
suggests cJun N-terminal kinase JNK as the MAPK mediating cJun phosphorylation [87]. 
Interestingly, our study in granulopoietic cells indicated a cJun phosphorylation to be 
mediated by a different member of the MAPK family, p38MAPK, acting as the 
downstream effector of MKK6. The MKK6-p38MAPK triggered phosphorylation thereby 
showed a time dependent character with exhausting cJun phosphorylation levels coming up 
at the 8 hour time point after MKK6 induction followed by a subsequent decline of 
phospho-cJun levels in case of longer lasting signal transduction periods. One could 
hypothesize, that these changes in the phosphorylation status of cJun might reflect an 
alteration of the composition of the p38 isoforms found to be expressed at a particular 
stage of the MKK6-p38MAPK driven conversion process. As demonstrated by Pramanik 
et al [27] the p38MAPK family members have opposing effects on the regulation of both 
cJun expression and activation. P38β was shown to potentiate the transcriptional activity of 
cJun mediating the phosphorylation of its N-terminal domain, whereas the γ and δ isoforms 
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predominantly suppress the cJun trans-activation by MKK6 [27]. Based on these findings 
one could hypothesize that the MKK6-driven changes of the transcriptional program that 
underlie G to Mo lineage conversion might include an alteration in the p38α, β, γ, and δ 
expression levels. A shift in the p38 isoform expression profile could in turn affect the 
signal transduction downstream of MKK6-p38MAPK converting an activating p38 signal 
into a suppressive. In support, monocytes and granulocytes found in RA patients showed a 
diverse isoform expression pattern [42]. In conclusion, the intriguing findings regarding 
the opposing functions of the p38 isoforms open a new direction for our prospective 
investigations. Further examinations of the MKK6-p38MAPK triggered modulations of the 
transitional program identified KLF4, a known critical regulator of monocytic 
differentiation to be induced in a MKK6-dependent manner. The results demonstrated a 
KLF4 upregulation to occur on the transcriptional as well as the protein levels. Time 
course analysis suggested the observed KLF4 induction to attribute to secondary effects of 
MKK6-triggered transcriptional changes. Beside the identification of key transcriptional 
factors driving G to Mo lineage conversion we focused on a more detailed analysis of the 
MKK6-p38MAPK signalling cascade. Short term induction of MKK6-p38MAPK was 
found to be sufficient to trigger the transcriptional signature described above that in turn 
reprograms granulocytic cells and drives the differentiation into the monocytic lineage. 
Furthermore, the data demonstrated low levels of p38MAPK activation, likely mimicking 
the physiological situation, to be sufficient to trigger a monocyte differentiating program, 
thus redirecting granulocytic cells to monocytes. Interestingly, recent studies identified an 
alternative, MAPKK independent mechanisms triggering p38MAPK activation - the 
TAB1-dependent autophosphorylation. TAB1, an adaptor protein classically involved in 
the signal transduction of the MAPKKK TAK1, was found to directly interact with 
p38MAPK inducing the activation of this MAPK by an autocatalytic mechanism. Ge at al 
further identified external stimuli, e.g. TNFα, to be capable to trigger the TAB1-induced 
p38MAPK phosphorylation [88;89]. Based on these novel findings one could hypothesize, 
that under certain circumstances such p38MAPK autoactivation mechanism may 
participate in the signalling network driving the p38MAPK-dependent G to Mo 
conversion.  
 
In summary, a detailed analysis of the basic molecular mechanisms driving G to Mo 
lineage switch was performed within the study. Based on the obtained results we could 
identify key factors mediating the conversion process and gain further insight into the 
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regulatory mechanisms guiding the MKK6-triggered modulations of the transcriptional 
network. Figure 23 summarizes the main findings observed during the study and 
schematically illustrates the signalling cascade driving G to Mo conversion.  
 
 
 
 
 
 
 
 
 
 
Figure 23. Granulocyte to monocyte lineage conversion 
– the signalling cascade. Activation of p38MAPK by MKK6 
triggers the upregulation of cJun and downregulation of C/EBPα, 
transcriptional changes underling G to Mo lineage shift. The 
conversion process can be interfered with by overexpression of the 
dominant negative form of cJun (DN cJun). Furthermore, inhibition 
of signal transduction downstream of p38MAPK by the specific 
inhibitor (SB203580) abolishes the MKK6-dependent transcriptional 
changes. In addition, stabilization of C/EBPα levels can be achieved 
in the presence of the proteasome inhibitor (MG132). 
 
 
In addition to the analysis of the molecular mechanisms of the granulocyte to monocyte 
conversion we aimed to investigate external stimuli able to trigger the described lineage 
switch. The examined p38MAPK signalling cascade is known to be a common pathway for 
the transduction of inflammatory stress signals [90]. Based on this knowledge we tested 
several combinations of pro-inflammatory cytokines for their ability to reprogram 
granulocytic cells to monocytes. The most prominent shift into the monocytic direction 
could be achieved by a cocktail of GM-CSF/TNFα/IL-1β. These cytokines are very 
prominent in the pro-inflammatory milieu found in inflamed joints of rheumatoid arthritis 
(RA) patients [68-71].  
 
RA is a chronic inflammatory autoimmune disease associated with the destruction of 
affected joints. The inflamed synovium consists of diverse cell populations, including 
monocytes/macrophages, granulocytes, synovial fibroblasts, B cells, and T cells. All 
populations contribute in their own way to the promotion and perpetuation of the disease 
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[91]. Classically, granulocytes are thought to be among the first cells to arrive at site of 
inflammation. As the primary effector cells of the innate immune response they contribute 
to the progression of inflammatory process by the induction of the respiratory burst. Beside 
the release of the granule content, activated granulocytes are capable of producing pro-
inflammatory cytokines, central to the promotion of inflammation [48;92]. Numerous 
studies highlights granulocytes as the main participants in the induction as well as 
perpetuation of chronic inflammatory diseases [92]. As an example, granulocyte depletion 
was shown to block RA induction in K/BxN mouse RA model, highlighting the 
indispensable role of granulocytes for disease initiation [93]. In humans, granulocytes were 
found to invade the synovial fluid of patients with RA, during acute inflammation and in 
flare of the disease, thus contributing to the joint destruction through the release of granule 
enzymes and reactive oxygen metabolites [52;94;95]. Joint inflammation is thereby 
characterized by the presence of large quantities of immune complexes and high levels of 
pro-inflammatory cytokines, whereby TNFα and IL-1 were found to be the major 
cytokines driving the pathogenesis of RA [96]. Our study highlights such pro-
inflammatory cytokines as a main stimulus triggering the conversion of granulocytic cells 
into monocytes. Although the occurrence of such lineage shift was not shown in vivo so 
far, based on our in vitro findings we raised the question for the impact of the observed G 
to Mo switch in the course of chronic disease progression. 
Numerous studies revealed that in addition to granulocytes both monocytes and synovial 
macrophages could be considered as critical players in RA. These cells are involved in the 
initiation and perpetuation of inflammation, leukocyte adhesion and migration, matrix 
degradation and angiogenesis by secretion of chemokines, cytokines, growth factors, 
proteases and other mediators [97]. A further contribution to disease progression is 
mediated by the bone destructive activity of monocytes, which were shown to undergo 
osteoclast differentiation upon contact with the appropriate signals. Synovial fibroblast-like 
cells and activated T cells found in synovial membrane appear as the most important cell 
types, providing the necessary signals for osteoclasts induction [98;99]. The key molecules 
driving the osteoclast differentiation was found to be the receptor activator of nuclear 
factor (NF)κB ligand (RANKL), expressed locally in the synovial tissue [100]. Another 
key mediator for osteoclast formation is TNFα. It is not only an inducer of RANKL 
expression but also directly enhances the differentiation and activation of osteoclasts 
through the interaction with the TNFα-receptor type 1. The concomitant presence of TNF 
thus potentiates the effect of RANKL and boosts osteoclast formation. Signalling through 
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TNFα-receptor type 1 involves mitogen-activated protein kinases and NFkB [101]. Of 
particular note, activation of p38MAPK pathway was thereby shown to play a pivotal role 
in the TNF-induced osteoclast differentiation [102].  
Our study analyzed the potential of pro-inflammatory cytokines, prominent in the synovial 
fluid, as a trigger for the granulocyte to monocyte conversion, suggesting the described 
lineage shift as a novel mechanism participating in the progression of RA pathogenesis. 
However, validations in mouse model are required to evaluate the in vivo relevance of the 
observed phenomenon. So far, based on the findings obtained from primary, in vitro 
differentiated cells we hypothesize the MKK6-p38MAPK dependent G to Mo lineage 
conversion to contribute to the perpetuation of RA progression by at least two mechanisms. 
On the one hand, the switch into the monocytic lineage generates a cell type responsible 
for the prolonged and excessive production of pro-inflammatory cytokines, central to the 
pathogenesis of inflammatory bone and joint destruction. On the other hand, the redirection 
into the monocytic cell subset enlarges the pool of monocytes capable to undergo 
osteoclast differentiation in the synovial inflammatory tissue. The local accumulations of 
osteoclasts in turn triggers bone erosions characteristically found in the inflamed joints of 
RA patients (Fig. 24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. MKK6-p38MAPK-dependent G to Mo conversion – a model for the 
contribution to RA progression. Stimulation with pro-inflammatory cytokines triggers the MKK6-
p38MAPK signalling cascade, which in turn drives the upregulation of the critical monocytic transcription 
factor cJun and the downregulation of the granulocytic factor C/EBPα, thus, promoting G to Mo conversion. 
The impact of Mo and G for RA progression is illustrated.  
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In conclusion, identification of the phenomenon of MKK6-p38MAPK dependent 
granulocyte to monocyte switch might provide new insights in our understanding of the 
nature of chronic inflammatory diseases. In addition to RA, which was taken in our study 
as a prototype of such an disorder, a variety of common diseases are known to be driven by 
chronic inflammation, including the most prominent ones such as inflammatory bowel 
disease, atherosclerosis and psoriasis [103-105]. As chronic inflammation is known to 
accompany the development and/or progression of autoimmune diseases it would be 
intriguingly to further extend the list by well known, severe autoimmune disorders 
including multiple sclerosis,  type 1 diabetes mellitus, and systemic lupus erythematosus  
[106-108].  
Beside the presumed impact of G to Mo conversion on the initiation and/or perpetuation of 
chronic inflammatory diseases as well as autoimmune disorders we propose the observed 
lineage switch as a novel mechanism participating in the progression of inflammatory 
processes in general and, therefore, open new perspectives for further investigations. 
Central to them is the validation of the in vivo relevance of the observed phenomena. RA 
mouse models could be used for the initial approval of the occurrence of such G to Mo 
switch in vivo. In case of promising results the study could further be extended to a variety 
of additional, inflammation-driven disease models.  
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